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Every year, HIV-positive adolescents add to the growing number of HIV-infected individuals. In fact, as of
2005, 50% of newly diagnosed persons with HIV worldwide were youth with an estimated 10.3 million
between the ages of 15 and 24. Adolescents will live with HIV 20 years longer than their adult counterparts,
but disease progression in them is less understood. It is well known that immune activation is prognostic of
chronic disease progression in adults and is often reduced when subjects go on therapy. It is unclear whether
immune activation is entirely eliminated in adolescents on therapy. To date, studies of HIV-positive
adolescents have been limited by design and methodology, resulting in a lack of research addressing the
relationship between outcome of antiretroviral therapy in adolescents and immune activation. To this end, we
designed a study to examine the relationship between therapeutic outcomes and immune activation in HIV-
positive adolescents. We assembled a cohort of 35 HIV-infected and 12 healthy adolescents and measured
immune activation (CD38,CD38/HLA-DR, Ki67) in both baseline and longitudinal data. As expected, cell
turnover was greatly increased in memory CD4 T cells over time. We found that levels of immune activation
in both CD8 and CD4 T cell subsets was elevated in viremic subjects at baseline and after long-term therapy.
One clear distinguishing factor of pathogenic HIV-infection is increased microbial translocation, which can be
measured by CD14 release by activated monocytes. We report sustained elevation of sCD14 in viremic
adolescents, which directly correlated to immune activation. Our results show that adolescents who are not
therapy compliant have elevated immune activation and turnover. Collectively, our results show that in the
presence of suboptimal therapy measures associated with disease progression are elevated. Therefore, it is
necessary to reconsider current treatment guidelines in adolescents to promote optimal adherence and
virologic control in this growing population of HIV-infected individuals.
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ABSTRACT 
IMPACT OF HARRT ON T CELL ACTIVATION IN HIV-INFECTED 
ADOLESCENTS  
Danielle Haney 
Michael R. Betts 
Every year, HIV-positive adolescents add to the growing number of HIV-infected 
individuals. In fact, as of 2005, 50% of newly diagnosed persons with HIV worldwide 
were youth with an estimated 10.3 million between the ages of 15 and 24.  Adolescents 
will live with HIV 20 years longer than their adult counterparts, but disease progression 
in them is less understood. It is well known that immune activation is prognostic of 
chronic disease progression in adults and is often reduced when subjects go on therapy. 
It is unclear whether immune activation is entirely eliminated in adolescents on therapy. 
To date, studies of HIV-positive adolescents have been limited by design and 
methodology, resulting in a lack of research addressing the relationship between 
outcome of antiretroviral therapy in adolescents and immune activation.  To this end, we 
designed a study to examine the relationship between therapeutic outcomes and immune 
activation in HIV-positive adolescents. We assembled a cohort of 35 HIV-infected and 12 
healthy adolescents and measured immune activation (CD38,CD38/HLA-DR, Ki67) in 
both baseline and longitudinal data. As expected, cell turnover was greatly increased in 
memory CD4 T cells over time. We found that levels of immune activation in both CD8 
and CD4 T cell subsets was elevated in viremic subjects at baseline and after long-term 
therapy. One clear distinguishing factor of pathogenic HIV-infection is increased 
microbial translocation, which can be measured by CD14 release by activated monocytes. 
We report sustained elevation of sCD14 in viremic adolescents, which directly correlated 
 v 
to immune activation. Our results show that adolescents who are not therapy compliant 
have elevated immune activation and turnover. Collectively, our results show that in the 
presence of suboptimal therapy measures associated with disease progression are 
elevated. Therefore, it is necessary to reconsider current treatment guidelines in 
adolescents to promote optimal adherence and virologic control in this growing 
population of HIV-infected individuals. 
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Chapter 1: Introduction 
Overview 
 
Although the immune system is efficient at recognizing and clearing pathogens, 
certain microorganisms can evade the immune response and ultimately cause death. One 
such pathogen is Human Immunodeficiency Virus (HIV), which primarily infects and 
replicates in CD4 T helper cells (Klatzmann et al., 1984b; Douek et al., 2002). HIV 
replication results in host cell death, latent infection or further infection of surrounding 
CD4 T cells. To combat infection, CD8 T cells identify and kill target cells by releasing 
cytotoxic molecules and secreting cytokines (Millard et al., 1984; Podack and 
Konigsberg, 1984; Podack et al., 1985; Badovinac and Harty, 2006). While CD8 T cells 
can impact viral replication during acute HIV infection, it is clear from primate studies 
that HIV/SIV is able to elude the immune system and escape detection from CD8 T cells 
(Brenchley et al., 2010). As a result of chronic exposure to antigen, CD8 T cells become 
hyper activated, dysfunctional (Betts et al., 2006; Betts and Harari, 2008), and 
ultimately exhausted (Day et al., 2006; Yamamoto et al., 2011). As such, the diminished 
functional capacity of HIV-specific CD8 T cells, coupled with the massive depletion of 
CD4 T cells renders the HIV-infected host unable to clear HIV infection and combat 
otherwise benign pathogens. 
 Over the last thirty years, there have been significant advancements in the design 
and development of antiretroviral therapies that have allowed HIV-infected patients to 
gain control of their disease and live relatively normal lives.  The most standard course of 
treatment is highly active retroviral therapy (HAART), a cocktail of drugs that inhibits 
multiple steps of HIV viral replication.  When used effectively, HAART decreases viral 
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replication and results in partial immune recovery and long term survival. However, in 
patients on therapy, virus persists in long-lived reservoirs, which are a source of viral 
replication (Blankson, 2006). Treatment interruption and lapses in adherence allow viral 
recrudescence that can result in renewed T cell depletion and the appearance of drug 
resistance mutations that contribute to therapy failure. Thus, HAART ultimately 
increases the duration of time a patient can survive with the virus, but is incapable of 
eliminating the viral reservoir within the lifetime of an infected individual (Finzi et al., 
1997; Blankson et al., 1999; Finzi et al., 1999). While it is fairly well established how 
HAART affects viral course in adult HIV-positive subjects, several unanswered questions 
remain as to how HAART may affect other subject groups, like adolescents and young 
adults. Some of these questions include: Does HAART effectively reduce levels of 
immune activation and viral load? If so, are these levels sufficiently reduced to dictate a 
better disease course? A goal of this thesis is to determine the effectiveness of HAART on 
viral load and immune activation reduction in adolescents. 
Currently, 50% of new incident HIV infections occur in adolescents aged 13-24. 
Treatment of these subjects is more complex because they are less likely to comply with 
therapy regimens. Poor adherence to therapy results in increased viral replication, drug 
mutations and ultimately virologic failure. A large body of work has addressed the effects 
of HAART in adults, but thus far research in HIV-positive adolescents is limited.  
Because adolescents will live longer with the disease those infected in adulthood, it is of 
the utmost importance to understand how their immune systems respond to the virus 
and how reduced adherence to HAART will impact viral dynamics. The goal of my thesis 
is to elucidate the effects of HIV on T cell activation and function in HIV+ adolescents.  
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HIV History, Biology and Pathogenesis 
In 1981, an increased incidence of Kaposi Sarcoma (KS), a rare form of benign 
cancer, appeared in homosexual men in New York (Hymes et al., 1981). Coincident with 
this increase in KS was the emergence of a rare lung infection, Pneumocystis carinii, 
which appeared in IV drug users and homosexual men (Masur et al., 1981). In addition 
to pneumonia, infection was associated with substantial depletion of CD4 T cells from 
the peripheral blood of infected patients. Researchers isolated the infectious agent from 
the inflamed lymph nodes of individuals and found the agent to possess characteristics 
common to retroviruses (Barre-Sinoussi et al., 1983; Klatzmann et al., 1984a). Further 
study revealed that the virus was cytopathic to CD4 T cells (Klatzmann et al., 1984a). 
This virus is now known as the Human Immunodeficiency Virus (HIV), the virus that 
causes AIDS (Acquired Immunodeficiency Syndrome). As of 2009, an estimated 33.3 
million people are living with HIV/AIDS and 2.6 million people were newly infected. A 
staggering 1.8 million deaths are attributed to HIV each year (Cohen et al., 2011). 
Although we know much about the disease and its impact on the body, a successful 
vaccine has yet to be developed. 
 In adults, HIV is typically acquired from exposure at mucosal surfaces through 
unprotected sexual contact or through intravenous or percutaneous inoculations (Cohen 
et al., 2011). Adolescents acquire HIV through high risk sexual behavior but a large 
number acquired HIV as infants through mother to child transmission (Catallozzi and 
Futterman, 2005). Upon exposure, HIV targets and primarily infects CD4 T helper cells, 
but can also infect macrophages and other antigen presenting cells.  In the case of CD4 
infection, the HIV envelope protein, gp120 fuses with the CD4 cell surface receptor and 
either chemokine receptor type 5 (CCR5) (Berson et al., 1996; Deng et al., 1996; Rucker 
et al., 1996) or CXC chemokine receptor type 4(CXCR4) (Feng et al., 1996). Once inside 
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the cell, the virus utilizes the host’s cellular machinery to replicate and produce new 
virions, which bud from the host cell and further propagate in surrounding cells and 
tissues, including the mucosa and draining lymphoid tissues (Cohen et al., 2011).  
The acute phase of infection occurs a few weeks post-transmission and is 
characterized by high levels of viral replication. Concomitant with massive viral 
replication is the depletion of mucosal (Brenchley, 2004) and peripheral blood CD4+ T 
cells (Daar and Ho, 1991).  After the initial peak in viremia, HIV viral load decreases to a 
“set point” of 103 to 104 copies of viral RNA per milliliter of plasma and typically remains 
at this level for 5-10 years (Cohen et al., 2011). It was initially thought that set point was 
directly correlated with progression to AIDS, wherein subjects with high set points 
progressed to AIDS more quickly than those individuals with lower set points (Mellors et 
al., 1995). However, it is now known that plasma HIV RNA level is not an independent 
marker of disease progression (Rodriguez et al., 2006). Although subjects are 
asymptomatic during chronic infection, there is continuous viral replication and CD4 T 
cell attrition during this phase. As a result of CD4 T cell depletion, CD4 mediated help to 
both CD8 T cells and B cells is impaired resulting in decreased killing ability and 
antibody production, respectively (Rowland-Jones, 2003). 
Because the virus is continually present, there is constant pressure on both the 
innate and adaptive immune systems to produce cytokines, which results in immune 
hyperactivation. Over time, hyperactivation of CD8 T cells leads to a state of exhaustion, 
which causes desensitization to antigen (Moir et al., 2011). CD4+ T cell attrition and 
impaired CD8 T cell function contributes to a dysfunctional immune state. The 
combination of these factors results in acquisition of opportunistic infections that 
characterize AIDS and result in death of the host.  
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Immune Response to HIV 
Humoral Immunity 
B cells produce antibodies to combat invading pathogens. These antibodies can 
induce antibody-dependent cell-mediated cytotoxicity (ADCC) or sterically hinder the 
interaction of the pathogen with an uninfected cell in a process called neutralization. 
Most vaccines are antibody-based and rely on these antibodies to neutralize the 
infectious agent.  It has recently been suggested that future vaccine design should focus 
on targeting HIV neutralizing antibodies at mucosal sites in order to block HIV entry 
(McMichael et al., 2010); however, due to the variability and structure of the HIV 
envelope, these antibodies would need to be broadly neutralizing to protect against a 
wide variety of HIV strains. There have been several studies in monkeys where the 
administration of broadly neutralizing antibodies at mucosal sites has led to protection 
against subsequent simian immunodeficiency virus-HIV chimera (SHIV) challenge 
(Hessell et al., 2009); however, similar results have yet to be achieved with humans. In 
fact, there are several limitations in protections from broadly neutralizing antibodies 
including rapid escape mutations (Richman et al., 2003; Wei et al., 2003; McElrath and 
Haynes, 2010) induction of non-neutralizing or neutralizing strain-specific antibodies 
(Kwong et al., 2002) and antibody binding-induced confirmation changes (Kwong et al., 
2002). There have, however, been recent studies showing that some HIV infected 
individuals can develop a range of neutralizing antibodies, a function that was previously 
thought to be difficult (McElrath et al., 2008; Stamatatos et al., 2009; Mikell et al., 
2011). Therefore, future studies should continue to address ways to overcome structural 
and biological impediments on the effectiveness of broadly neutralizing antibodies for 
use in an HIV vaccine. 
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Innate Immunity 
Natural Killer (NK) cells, characterized by their large granular structure, are a 
major arm of the innate immune system. NK cells are multifunctional and make up 
~10% of the circulating blood population (Herberman et al., 1975; West et al., 1977). 
Unlike T and B cells, these cells do not express antigen receptors but do express multiple 
activating and inhibitory receptors, such as killer cell immunoglobulin like receptors 
KIRs (Vilches and Parham, 2002) in response to pro-inflammatory stimuli, NK cells 
migrate to the site of infection where, much like CD8 T cells, they release cytolytic 
molecules including perforin, granzymes, and granulysin (Timonen et al., 1981). NK cells 
also produce IFN-γ which activates macrophages, promotes CD4 Th1 differentiation and 
has several anti-viral effects (Cooper et al., 2001). 
Recently, it has been shown that NK cells play a role in the defense against HIV.  
Expression of KIR3DS1, an activating KIR gene, and its ligand, Bw4 is associated with 
slower HIV-1 disease progression (Martin et al., 2007). NK cells lyse infected target T 
cells during HIV infection, although this lysis effect is somewhat weak and dependent on 
the presence of NK surface inhibitory receptors (De Maria et al., 2003; Mavilio et al., 
2003) Furthermore, chemokines secreted by NK cells can block viral entry in vitro 
(Costa et al., 2003). Additionally, elevated antibody dependent cellular toxicity, an 
important function of NK cells, is correlated with lower risk of death when controlling for 
outside factors like CD4 T cell count and viral load (Forthal et al., 2001a; Forthal et al., 
2001b; Bernstein et al., 2004) 
HIV-specific CD4 T cells 
CD4 T cells are an integral part of an effective immune response and are often 
referred to as T helper cells.  They promote immune control by providing help to CD8 T 
cells and B cells. However, HIV-specific CD4 T cells are preferentially infected and killed 
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by the virus (Douek et al., 2002).  Severe depletion of CD4 T cells during HIV infection 
is tightly linked to opportunistic infections in AIDS patients and increased dysfunction in 
the CD8 T cell compartment (Kalams et al., 1999a; Altfeld and Rosenberg, 2000). 
Therefore, several groups have sought to determine the relationship between HIV-
specific CD4 T cell responses and viral load control. 
HIV subjects can be segmented into two separate groups, those who control viral 
replication and individuals who do not (progressors)(Pereyra et al., 2010). Several 
researchers have attempted to understand qualitative and quantitative differences in 
CD4+ T cell responses between progressors and controllers.  The frequency of CD4 T 
cells is inversely correlated to viral load but the ability for HIV-specific CD4 T cells to 
proliferate has been identified as one of the key factors in viral control (Rosenberg et al., 
1997; Pitcher et al., 1999; Wilson et al., 2000). Indeed, CD4 T cell proliferative capacity 
is diminished in patients with high viral load (Gea-Banacloche et al., 2000; Iyasere et al., 
2003) and is often restored upon initiation of HAART (Autran et al., 1997a; Emu et al., 
2005). In addition to proliferative capacity, HIV-specific CD4 cells also secrete cytokines 
in response to virus; therefore, several studies have focused on identifying cytokine 
expression patterns that may correlate to protection. Thus far, it has been established 
that long-term non-progressors (LTNP) possess HIV-specific CD4 T cells that produce 
both IL-2 and IFN-γ whereas subjects who cannot control the disease do not (Boaz et al., 
2002; Harari et al., 2004). It is unclear if diminished functionality observed in HIV-
specific CD4 T cells from progressors actually causes AIDS.  More than likely low 
functionality could be a consequence of the immune state during progression.  
HIV-specific CD8 T cells 
In 1986, HIV-specific CD8 T cells were identified in sereopositive individuals but 
their potential role in combating HIV disease progression was not known (Walker et al., 
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1986). Two separate groups reported initial evidence for HIV-specific CD8 T cell 
mediated control (Borrow et al., 1994; Koup et al., 1994). These studies showed a 
temporal association between HIV-specific CD8 T cell expansion and the resolution of 
acute viremia. Individuals with persistent viremia and lower CD4 T cell counts were less 
likely to have high HIV-specific CD8 T cell counts, suggesting a direct role for HIV-
specific CD8 T cells in disease progression. To extend these findings and directly test the 
hypothesis that CD8 T cells were necessary for viral control, researchers carried out 
experiments in rhesus macaques using the simian immunodeficiency virus (SIV) model. 
Using anti-CD8 monoclonal antibodies to deplete CD8 T cells in vivo, they showed that 
CD8-depleted primates were unable to control viremia, but upon restoration of CD8 T 
cell numbers the ability to control SIV replication was re-established (Jin et al., 1999; 
Schmitz et al., 1999). This initial work in humans and monkeys demonstrated a potential 
role for T cell based vaccines and motivated the field to determine potential mechanisms 
of control mediated by these cells. 
Further evidence for HIV-specific CD8 T cell control in HIV infection is the link 
between MHC Class I allele expression and HIV disease progression. Expression of 
certain MHC Class I alleles can often predict disease outcome. Subjects who are 
homozygous at any of the 3 HLA Class I loci (HLA-A, HLA-B, HLA-C) typically progress 
more rapidly to AIDS than those who are heterozygous (Goulder et al., 1997; Carrington 
et al., 1999). This heterozygosity is thought to increase the breadth of recognized viral 
epitopes resulting in better CD8 T cell-mediated control than subjects who are 
homozygous. However, in certain examples a narrowly directed HIV-specific CD8 T cell 
response can be effective at controlling viremia over time (Goulder et al., 1997). Subjects 
who maintain superior control of virus in the absence of therapy express HLA-B27 and 
B57 alleles (Kaslow et al., 1996; Migueles et al., 2000; Emu et al., 2008). CD8 T cells 
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recognize peptides presented by MHC Class I molecules therefore the association 
between certain MHC alleles and viral control further implicates CD8 T cells in the 
control of viremia.  
 CD8 T cell-mediated recognition of virus-infected cells induces rapid selection for 
viral escape mutants. The first evidence for CD8-mediated escape was shown in 1997 by 
several groups (Borrow et al., 1997; Goulder et al., 1997; Price et al., 1997). In two of 
these studies, escape was shown to occur during acute infection. Additionally, CD8 T cell 
escape was also shown to occur late in infection even after effective long-term control of 
virus and was associated with progression to AIDS. Subsequent studies in the SIV model 
have supported that CD8 escape occurs in the chronic (Allen et al., 2000; O'Connor et 
al., 2002) and acute (Evans et al., 1994; Evans et al., 1999) phase of infection. Therefore 
the evidence that HIV escapes from CD8 T cell mediated pressure is vast. Interestingly, 
escape mutations often confer negative fitness cost to the virus and may precede effective 
suppression of viremia.  
The expansion of HIV-specific CD8+ T cells and the concomitant decline of 
viremia has been one of the most convincing arguments for CD8 T cell control of viral 
replication. Several groups chose to determine if the control induced by HIV-specific 
CD8 T cells was the result of quantitative or qualitative events. MHC Class I tetramer- 
based studies demonstrated that the frequency of HIV-specific CD8+ T cells inversely 
correlated with viral load (Ogg et al., 1998). These results were limited to A2-restricted 
Gag and Pol-specific CD8 T cell responses and therefore were not reflective of the entire 
response to HIV. A more comprehensive study went on to establish that there was a 
positive correlation between viral load and the total HIV-, Env- and Nef-specific CD8 T 
cell frequency (Betts et al., 2001a). Conversely, other studies reported certain responses 
to viral proteins inversely correlated to viral load (Edwards et al., 2002). Therefore, it 
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can be seen that early studies involving a link between frequency and function of CD8 
T cells and plasma load were inconclusive. Moreover, the total frequency of HIV-specific 
CD8 T cells did not explain differential control of viral load in controllers versus 
progressors.  
In 2006, Betts et al. employed the use of polychromatic flow cytometry to 
characterize the CD8 T cell response in non-progressors. They found that subjects 
maintaining low viral loads possessed highly functional HIV-specific CD8 T cells. 
Conversely, the frequency and proportion of HIV-specific CD8 T cell response with the 
highest functionality inversely correlated with viral load in the progressors (Betts et al., 
2006). Furthermore, HIV-specific CD8 T cells in non-progressors were superior in their 
ability to proliferate and degranulate upon antigen encounter. This study was the first to 
determine that the quality of the functional response was a better correlate of HIV 
disease progression (Betts et al., 2006). Although a single correlation factor has yet to be 
identified, perforin-mediated killing and proliferative capacity is enriched in patients 
who control viral load (Migueles et al., 2002; Migueles et al., 2008; Hersperger et al., 
2010a) suggesting that HIV-specific CD8 T cells from subjects who maintain killing 
function are most effective at suppressing viral replication.  
Finally, when cellular functionality is altered, the importance of CD8 T cells 
becomes evident. In studies using LCMV, a murine model of acute and chronic viral 
infection, it was revealed that CD8 T cells become exhausted after prolonged antigen 
exposure (Blackburn et al., 2009). Exhaustion is characterized by diminished function, 
proliferation of CD8 T cells and the expression of exhaustion markers like PD-1, a 
negative regulator of activated T cells. Recently, studies in HIV-positive humans have 
shown that HIV-specific CD8 T cells expressing higher levels of PD-1 also have impaired 
effector function and correlate with higher viral loads (Day et al., 2006; Petrovas et al., 
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2006; Younes et al., 2007). However, it is becoming increasingly clear that expression 
of multiple inhibitory receptors indicates an exhausted phenotype (Yamamoto et al., 
2011) in chronically infected humans. Future studies are necessary to determine the 
contribution of immune exhaustion to HIV disease progression. 
The role HIV-specific T cell responses in adolescents 
HIV-specific CD4 and CD8 T cells play an integral part in the reduction in viral 
replication and progression to HIV (Rosenberg et al., 1997; Betts et al., 2001a; Boaz et 
al., 2002; Pantaleo and Koup, 2004; Betts et al., 2006; Duvall et al., 2006). In HIV-
positive adults, it is known that the presence of polyfunctional CD8 T cell responses are 
correlated with reduced viral load (Betts et al., 2006). Adults who have a higher viral 
load and progress to AIDS are more likely to have a less polyfunctional CD8 T cell 
response (Betts et al., 2006). While HIV-specific T cell responses have been fairly well 
characterized in adults, the role of these responses in adolescents remains unclear. 
The degree of T cell functionality or the ability of the T cell to respond to 
antigenic stimulation is related to age (Buseyne et al., 2005a; Prendergast et al., 2011). 
For HIV-positive newborns, an immature immune system combined with poor antigen 
presentation impairs the generation of HIV-specific T cells during the first months of life 
(Buseyne et al., 1998).  As a consequence, untreated children have high levels of 
persistent viremia, which promotes immune activation and decreases the chance for 
recovery post-therapy initiation. For children on therapy, as well as adults, viral 
suppression is often associated with a decreased frequency of HIV-specific IFN-γ 
producing CD8 T cells (Buseyne et al., 2005a). When responses are detected, it is the 
frequency of gag-specific CD4 and CD8 T cell responses that are associated with virologic 
control in infants and children (Prendergast et al., 2011). In HIV-positive adolescents 
antigen-specific CD8 T cell functional responses are even less studied than in children. 
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When the functionality of CD8 T cells in adolescents has been examined, it is often 
studied and analyzed in conjunction with T cell functionality in children from 0-9 years 
of age making it difficult to draw conclusions about the contribution of these responses 
to viral control  
Immune Activation 
A hallmark of HIV infection is severe cellular depletion in the CD4 T cell 
compartment (Hunt et al., 2008). Initially, it was believed that CD4 T cell depletion was 
due to direct killing of infected CD4 T cells, but the widespread immune damage was far 
too severe to be solely attributed to HIV-induced CD4 T cell destruction. For this reason, 
several groups sought to determine the non-antigen specific mechanisms that caused 
CD4 T cell attrition. In the early 90s, several groups showed that HIV induced immune 
activation primarily impacted uninfected bystander cells leading to apoptotic cell death 
(Groux et al., 1992; Finkel et al., 1995). It is now understood that chronic widespread 
immune activation is the distinguishing characteristic of pathogenic HIV infection 
(Giorgi et al., 1993; Liu et al., 1997). Immune activation is the key difference between 
pathogenic and non-pathogenic infection. For example, non-progressive infection is 
characterized by high viral load, controlled immune activation and a lack of progression 
to AIDS.  In contrast, progressive infection is characterized by uncontrolled immune 
activation and disease progression (Van Rompay et al., 2004). Immune activation is 
characterized by accelerated proliferation, exhaustion, and T cell depletion that results in 
reduced regenerative capacity of the immune system. Administration of antiretroviral 
therapy reduces immune activation through direct inhibition of HIV viral replication. 
Importantly, reducing immune activation results in a more favorable disease outcome 
(Kalams et al., 1999b; Hunt et al., 2003a). 
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There are several markers that have been used to identify T cell activation in 
vitro, including CD38, HLA-DR, CD25, CD69, CD70, tumor necrosis factor receptor type 
II and Beta2-microglobulin (Liu et al., 1997). CD38/HLA-DR co-expression was one of 
the earliest combinations of activation markers identified to directly correlate with 
increased viral loads (Giorgi et al., 1993). Elevated levels of CD38 have been directly 
associated with a higher propensity to develop AIDS than those with lower CD38 levels 
(Liu et al., 1997). Moreover, elevated levels of CD38+CD8+ T cells were found to be 
better predictors of disease progression than viral load or CD4 T cell count (Wilson et al., 
2004). Further, upon therapy initiation, the levels of CD38 in the blood and lymph node 
decreased coincident with plasma viremia albeit not to levels similar to those at baseline 
(Benito et al., 2004; Yang et al., 2005).  
Increased T cell turnover is now known to be a consequence of increased immune 
activation during HIV infection. However, it was previously debated whether the rapid 
rise in CD4 counts in the blood after HAART initiation was	  due to this process. Some 
groups postulated that the rise in CD4 T cell counts was largely due to lymphocyte 
redistribution and not a result of increased turnover (Sprent and Tough, 1995). 
Supporting this hypothesis, CD4 T cell telomere length in HIV infected persons was not 
found to be significantly shorter than that of their uninfected counterparts suggesting 
that these cells were not undergoing rapid turnover (Wolthers et al., 1996). To directly 
address if T cell turnover occurs during HIV infection, several groups employed the SIV-
rhesus macaque model (Mohri et al., 1998; Rosenzweig et al., 1998). Using 
Bromodeoxyuridine (BRDU), a dye that incorporates into the DNA of proliferating cells, 
T cell turnover was quantified in living tissues. Animals with high viral loads had 
increased BRDU incorporation as well as higher rates of decay in CD3+CD4+, 
CD3+CD4-, CD3-CD8+CD16+ and CD3-CD20 cells, suggesting that increased turnover 
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occurs in each lymphocyte population. These results were further supported by the 
observation that CD4 and CD8 T cell turnover rates were 2-3 fold higher in infected 
primates (Mohri et al., 1998; Rosenzweig et al., 1998).  Taken together, these data 
showed that there was, in fact, increased turnover during HIV-like infection in each 
lymphocyte subset.   
Studies were extended to humans using deuterated glucose (D-glucose) to 
determine relative rates of turnover in vivo. Similar to findings in rhesus macaques, CD4 
and CD8 turnover rates in HIV-infected subjects decreased over time with therapy 
(Hellerstein et al., 1999; Mohri et al., 2001). These results were further confirmed in 
human in vitro studies using Ki67, a marker of proliferation and cell cycle entry. The 
percentage and absolute number of Ki67+ CD4 and CD8 T cells was elevated in infected 
subjects compared to uninfected counterparts (Hazenberg et al., 2000c). After HAART 
therapy, proliferation of CD8 and CD4 T cells decreased, as did viral loads. Theoretically, 
increased T cell turnover could be a reflection of homeostatic proliferation driven by cell 
losses induced by the virus. In this study however there was an initial decrease in CD4 T 
cell count after therapy despite the relative low initial numbers. This suggests that 
proliferation is a result of immune activation and not homeostasis. 
Causes of Immune Activation 
To date, the underlying cause of immune activation in HIV-positive humans 
remains unclear, however, a combination of factors have been implicated as contributing 
to activation. Firstly, the virus itself is thought to promote immune activation through 
the binding of gp120 to CD4 or CCR5 (Decrion et al., 2005). This binding event results in 
increased intracellular signaling thus promoting cellular activation and further infection. 
Indeed, studies have shown that the addition of CCR5 antagonists result in decreased 
immune activation (Ahuja et al., 2008) and that elevated CCR5 surface density is linked 
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to reduced CD4 T cell restoration (Vincent et al., 2006). Additionally, host innate 
immune responses have been implicated. Macrophages, DCs, and NK cells release pro-
inflammatory cytokines like TNF, IL-6, and IL1-β during infection. These cytokines 
activate adaptive immune responses resulting in HIV-specific and bystander cell 
activation (Engram et al., 2010). Furthermore, massive CD4 T cell depletion during HIV 
leads to suboptimal control of persistent viruses like CMV and EBV. Reactivation of 
these viruses exacerbates the immune response and the inflammatory environment 
(Bafica et al., 2004). Finally, CD4 T cell depletion during HIV infection occurs primarily 
in the gut associated lymphoid tissues (GALT) and is associated with the disruption of 
the mucosal barrier (Brenchley et al., 2004). This causes the translocation of microbial 
products from the intestinal tract, resulting in detection by the immune system. These 
by-products, including LPS and CpG, activate immune cells through TLR ligation and 
contribute to chronic immune activation (Brenchley et al., 2006). Taken together, these 
studies suggest that one single factor does not contribute to the activated environment 
during HIV infection but it is most likely a combination of factors that contributes to 
overall activation.  
HAART: Highly Active Antiretroviral Therapy  
Presently, the most effective therapy for HIV infection is HAART, a cocktail of 
different viral inhibitors that each prevent specific steps in viral replication from 
occurring. These drug classes are: Entry Inhibitors, Nucleoside/Nucleotide Reverse 
Transcriptase Inhibitors (NRTI), Non-Nucleoside Reverse Transcriptase Inhibitors 
(NNRTI), Protease Inhibitors (PI), and Integrase Inhibitors (II). Entry inhibitors bind to 
the cell surface receptor, CCR5, and block the fusion of HIV GP120 with the host cell 
membrane (Lalezari et al., 2003; Root and Hamer, 2003; Liu et al., 2007). The second 
class of inhibitors (NRTIs) interferes with the reverse transcription step of HIV (St Clair 
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et al., 1987; Roberts et al., 1988).  Non-nucleoside Reverse Transcriptase Inhibitors 
(NNRTIs) are analogues of deoxynucleotides that are needed to synthesize DNA, but lack 
the 3’hydroxyl chain, and when incorporated into the growing cDNA genome, result in 
termination of replication (Jeffries, 1989; Merluzzi et al., 1990; Richman et al., 1991; 
Hsiou et al., 1998). The third class of viral inhibitors target HIV Protease. Protease 
inhibitors prevent the cleavage of viral proteins, which are translated as polyproteins, 
and thus interfere with replication within the host cell (Billich et al., 1995; Reedijk et al., 
1995). The final class of inhibitors target HIV integrase.  These inhibitors prevent the 
action of HIV integrase which functions to integrate the viral genome into the host 
genome allowing production of new viruses (Hazuda et al., 2000; Hazuda et al., 2004; 
Steigbigel et al., 2008). 
While HAART is efficient at inducing low to undetectable viral loads, it is 
essential that individuals are compliant with their therapy regimens. Without a rigid 
schedule of medication, HIV viral load is able to rebound, resulting in increased immune 
activation and decreased CD4 T cell counts and disease progression (Karlsson et al., 
2004; Hunt et al., 2006; Agwu et al., 2008). Additionally, while HAART intervention 
contributes to overall quality and duration of life, it is not a cure and should not be 
viewed as a perfect solution. When compared to both HIV-negative and long-term non-
progressor controls, CD4 T cell counts and T cell activation remain abnormal after 
therapy intervention (Benito et al., 2004; Gandhi et al., 2010). In fact, while HAART 
does control viral load, it does not eliminate the virus completely, for the viral reservoir 
does not appear to decay effectively during therapy (Chun et al., 1997; Finzi et al., 1997; 
Finzi et al., 1999; Lassen et al., 2006). Residual viremia affects immune recovery by 
causing elevated immune activation even while patients are on therapy (Karlsson et al., 
2004).  For these reasons, future studies are needed to determine the cause of prolonged 
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immune activation and its lasting impact on immune recovery even after therapy 
intervention. 
Adolescents and Immune Activation  
Overview 
  Compared to adults, adolescents will live with HIV on average 20 years longer 
than infected adults, but disease progression in them is less understood. While 
adolescents are commonly infected as infants via vertical transmission (mother-child) or 
through breast milk, new advances in therapy have reduced the rate of transmission 
from mother to child. In recent years, an increasing number of adolescents are also 
acquiring infection through behavioral routes, such as risky sexual acts and drug use. In 
fact, as of 2005, 50% of newly diagnosed persons with HIV worldwide are youth with an 
estimated 10.3 million between the ages of 15 and 24 infected. While antiretroviral 
therapies have proven successful at increasing lifespan, effective treatment of 
adolescents is particularly challenging because of their unique psychosocial issues, 
including gender power imbalance in sexual relationships, lack of safe sex education, 
perceived HIV disease stigma, and limited access to healthcare (Futterman, 2005). These 
factors can have a significant impact on the efficacy of therapeutic strategies to target the 
virus in adolescents, and thus must be carefully considered, because of the link between 
adherence to therapy and drug resistance in HIV infection. 
T cell turnover and Immune Activation in Adolescents 
Maintenance of adequate T cell numbers and diversity of the T cell repertoire are 
primary requirements for a functional immune system. During HIV infection, T cells are 
constantly being destroyed causing an imbalance in the T cell population, which leads to 
immune dysfunction and increased susceptibility to opportunistic infections. The 
thymus generates new cells which helps to replenish the T cell repertoire. For individuals 
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infected with HIV, this feature of the immune system can help restore the cellular 
compartments that were destroyed by the virus. This regenerative capacity is most 
robust in children and continually declines as the individual ages (Mackall et al., 1995; 
Douek et al., 1998; Vigano et al., 2000b). 
During the typical HIV disease course, the percentage and number of CD4 T cells 
declines over time whereas CD8 T cell counts either remain stable or rise (Ibegbu et al., 
1994; Rabin et al., 1995). When individuals initiate HAART, memory and naïve CD4 T 
cell counts increase and CD8 T cell numbers normalize. In HIV-infected adults, CD4 T 
cell levels do not return to pre-infection levels even if viral replication is controlled with 
therapy (Autran et al., 1997a; Surh and Sprent, 2008). Compared to adults on therapy, 
HAART-treated adolescents have higher recovery rates in naïve and memory T cell 
populations, suggesting that increased thymic capabilities in younger subjects promote 
immune restoration (Cohen Stuart et al., 1998a; Sleasman et al., 1999).  
To date there are few definitive studies on the effects of HAART on turnover in 
HIV-positive adolescents. Using Ki67 as a marker of proliferation to determine relative 
turnover, studies have shown that HIV-positive adolescents have higher Ki67-expressing 
naïve and memory T cell subsets than healthy controls, with the highest levels of Ki67 
being in the naïve CD8 T compartment (Flynn et al., 2007). Additionally, HIV-infected 
adolescents have significantly lower numbers of CD4 T cells than controls (Rudy et al., 
2002). In one report, increased Ki67 expression correlated with CD38/HLA-DR co-
expression on CD8 T cells suggesting that increased rates of proliferation were driven by 
increased immune activation (Starr et al., 2002b). There was no correlation or 
relationship found between Ki67 expression and therapy initiation. A possible 
explanation of this relationship is that therapy in adolescents is ineffective at decreasing 
turnover. Findings resulting from well defined cohorts, accurately defined activation 
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parameters, and T cell subsets will prove beneficial in determining therapeutic effects 
on the adolescent immune system.  
Although lymphocytes rebound following therapy in HIV infected adolescents, 
continued immune activation may negatively impact lymphocyte recovery. A link 
between immune activation and T cell recovery following HAART in HIV-positive 
adolescents can be found in a study designed to evaluate predictors of CD4 T cell loss. In 
this study they measured CD4 T cell counts and markers of immune activation (CD38, 
Ki67) at baseline and up to week 60 following therapy initiation (Rudy et al., 2006b). A 
subset of individuals with CD4 counts over 300 cells/µl reached viral suppression by 
week 24.  After 24 weeks on therapy, adolescents showed significant increases in CD4 T 
cell counts and decreases in CD8 T cell counts. However, these individuals were less 
likely to sustain this suppression if they had elevated levels of activated CD38/HLA-DR 
expressing CD8 T cells (Rudy et al., 2006a), suggesting that the advantage of higher CD4 
counts prior to therapy (Perez et al., 2001) is lost in the presence of immune activation. 
Indeed, children with lower levels of CD38/HLA-DR CD8 T cells have moderate 
increases in CD4 T cell counts and lower viral loads (Borkowsky et al., 2000; Starr et al., 
2002a). Taken together these studies demonstrate the impact of T cell activation on T 
cell recovery rates and virologic control in youth. They also suggest that it is necessary to 
reduce immune activation while on therapy to maintain viral suppression and recover 
CD4 T cell counts. 
Antiretroviral Treatment in Adolescents 
Antiretroviral treatment failure and subsequent drug resistance are major 
obstacles in long-term management of disease in HIV-infected youth. Adolescents who 
receive HAART have low adherence to therapy with rates ranging from 29-50% (Douglas 
et al., 2000; Rudy et al., 2001; Agwu et al., 2008a).  These rates are substantially lower 
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than the 90-95% adherence rates necessary for successful long-term viral control and 
prevention of drug resistance. Consequently, only 58% of youth reach viral suppression 
on therapy at week 24 of treatment compared to 80-90% of adults (Rudy et al., 2006b).  
As a result, a growing number of HIV-positive adolescents on HAART will likely undergo 
viral breakthrough and subsequent drug resistance. 
Effective strategies aimed at adolescents must preserve immunity, have a low 
dosing frequency, a low risk for therapy-associated toxicity, and a minimal risk for drug 
resistant viruses. As discussed previously, two major drug regimens are NNRTI or PI 
based. Both of these regimens are equally effective in early therapy, however, these 
regimens are not perfect. For example, increased drug resistance during NNRTI 
treatment results in persistent viral variants that can be detrimental in long-term 
patients (Cohen Stuart et al., 1998; Agwu et al., 2008a). Even after subjects are found to 
be resistant to therapy, they often continue on the same regimen (Gortmaker et al., 
2001). The addition of PI to the NNRTI regimen has been successful at reducing drug 
mutations in adults, so several groups turned their attention to investigating the effects 
of different combination therapy in children and adolescents (Hammer et al., 1997; 
Palella et al., 1998). A three-year prospective study in children (age birth-20) showed a 
67% reduction in risk of death when protease inhibitors were used (Gortmaker et al., 
2001).  Adolescents undergoing NNRTI treatment were more prone to drug resistance 
mutations than adolescents on protease inhibitors alone (Agwu et al., 2008b). 
Furthermore, since adolescents usually remain on NNRTI therapy, more mutations are 
likely to occur. However, while protease inhibitor therapy may be less prone to drug 
resistance, there are long-term metabolic side effects that should not be ignored. 
Therefore, careful consideration must be made when choosing therapeutic regimens for 
adolescents. Future studies should carefully examine the effect of different drug 
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combinations on immune activation, which is the strongest predictor of disease 
progression. 
Microbial Translocation in HIV+ Adolescents 
As discussed previously, microbial translocation is thought to be the driving force 
of immune activation in adults, but the role of microbial translocation has been 
understudied in HIV-positive adolescents. In HIV-positive infants other markers of 
microbial translocation such as sCD14, LBP and Endocab are increased in infants who 
delay treatment during the first six months of life compared to their HIV-exposed 
counterparts (Papasavvas et al., 2011). Soluble CD14, a marker of macrophage activation 
and increased microbial translocation, has been cited as the strongest predictor of death 
in adult HIV studies (Sandler et al., 2011). Therefore, increased levels of sCD14 even in 
the absence of immune activation could signify poor disease outcome. A recent study in 
children aged 0-17 years cited increased LPS and sCD14 levels in infected subjects 
compared to controls (Wallet et al., 2010) and, in contrast to adult reports, neither of the 
studies discussed found an association between immune activation and microbial 
translocation (Brenchley et al., 2006). Due to the long-term nature of the disease in 
adolescents and children, future studies should work to elucidate the association of 
sCD14 with HIV disease progression.  
Thesis Goals 
  Adolescents comprise an alarming portion of new HIV cases yearly. Moreover, 
the duration of their disease will be much longer than that of their adult counterparts. 
They will also be exposed to the effects of immune activation for the duration of their 
lifetime.  It is unclear whether this immune activation is entirely eliminated even in 
adolescents that strictly adhere to therapy let alone in the large number of adolescents 
who do not adhere. To date, studies of HIV-positive adolescents have been limited by 
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design and methodology resulting in a lack of research addressing the relationship 
between outcome of antiretroviral therapy in adolescents and immune activation in this 
patient group.  
In order to address this deficit in research of HIV-infected adolescents and to 
examine the relationship between therapeutic outcomes and immune activation in 
adolescents, we assembled a cohort of HIV-infected HAART-treated subjects and 
measured common markers of immune activation on lymphocytes from these subjects. 
We first chose to investigate the affects of HAART therapy on the activation levels of CD4 
T cells and CD8 T cells. To this end, we took a novel approach by examining the 
simultaneous expression of CD38, HLA-DR and Ki67 in the cohort. To date, most studies 
have been defined using naïve versus memory analysis and have been limited to 3-color 
flow cytometry. In my studies, we have taken advantage of polychromatic flow 
cytometry, which allows the examination of up to 18 colors simultaneously.  Using this 
technology, we investigated the expression of activation markers on multiple memory T 
cell subsets with the goal of determining if viral load preferentially correlates with 
activation, as well as, memory T cell definition, and microbial translocation. In addition 
to studying the effects of HAART on activation in adolescents this body of work also 
addresses the CD8 T cell response to HIV in adolescents. The goal of this thesis is to 
increase the understanding of the capacity of the adolescent immune system and its 
response to therapy, with the ultimate goal of informing future therapy regimens in this 
long-term patient population. 
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Chapter 2: An examination of Increased CD8+ T 
cell Activation in HIV+ adolescents on HAART 
Abstract 
 In 2006, 50% of new HIV infections occurred in adolescents aged 13-24.  In 
adults, immune activation directly correlates to HIV disease progression; however, 
immune activation in adolescents is not completely understood. We characterized 
immune activation markers on CD8 T cells from a cohort of adolescent subjects 
including 15 viremic (>50 copies RNA/ml), 17 aviremic (<50 copies RNA/ml), and 12 
HIV uninfected subjects. We used polychromatic flow cytometry to define the immune 
activation profile of CD8+ T cells by measuring simultaneous expression of CD38, HLA-
DR, Ki67 and Bcl-2. We observed increased immune activation on total memory, effector 
(CCR7-CD45RO-), effector memory (CCR7-CD45RO+) and central memory 
(CCR7+CD45RO+) CD8 T cell subsets. The frequency of CD38+CD8+ effector T cells 
directly correlated with viral load (p=.0366).  However, we did not find a correlation 
between viral load and CD4 T cell counts. Compared to aviremic subjects, sCD14 levels 
were higher in viremic subjects and were correlated with CD38 expression on central 
memory, effector and effector memory populations. Taken together, these results show 
that there is preferential activation across memory subsets and a direct relationship 
between viremia, activation and sCD14 levels in HIV+ adolescents. 
Introduction 
Adolescents and young adults comprise roughly 50% of new HIV infections in the 
United States (Futterman, 2005)  yet current therapy guidelines for this population are 
based on adult standards. Psychosocial issues in young adults make it difficult for this  
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Table II: Overview of Adolescent Cohort 
!
 Viremic 
 
Aviremic Healthy Healthy Donors 
for sCD14 
measurement 
# of Subjects 15 
 
17 12 43 
Plasma RNA 
(median) 
6,790 copies RNA 
per/ml  
< 50 
copies/RNA/ml 
N/A N/A 
CD4 T cell count 
(mean) 
505 cells/ml 732 cells/ml Not determined Not determined 
CD8 T cell count 
(mean) 
985 cells/ml 886 cell/ml Not determined Not determined 
Sex 6 males 
13 females 
10 males 
6 females 
6 male 
6 female 
28-male 
15-female 
 
Mode of 
Transmission 
4 Behavior 
11 Perinatal 
2 Behavior 
15 Perinatal 
N/A N/A 
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population to adhere to therapy guidelines (Futterman, 2005) Despite the numerous 
reports in children and adults, few studies have addressed the successful control of HIV 
by HAART therapy in adolescents. It has been suggested that adolescents have more 
thymic capacity than adults (Douek et al., 1998; Douglas et al., 2000). For example, 
adolescents have higher naïve CD8 and CD4 T cells counts, which may allow for 
favorable response to therapy (Douglas et al., 2000; Starr et al., 2002a). In fact, it has 
been shown that individuals with higher pre-treatment CD4 T cell counts are likely to 
rebound cell numbers close to that of aviremic controls (Perez et al., 2001). Adolescents 
will be lifelong carriers of the disease; therefore, it is of the utmost importance to 
understand the effectiveness of current therapies in this expanding population to 
determine if it is necessary to restructure their treatment regimens. 
Immune activation has been identified as a better predictor of disease 
progression than viral load (Rodriguez et al., 2006) or CD4 T cells counts in HIV-
infected adults (Giorgi et al., 1993; Liu et al., 1997; Giorgi et al., 2002; Rodriguez et al., 
2006). Immune activation is commonly assessed by measuring expression of Ki67, CD38 
or co-expression of CD38/HLA-DR (Giorgi et al., 1993; Sachsenberg et al., 1998a; 
Hazenberg et al., 2000c). Higher CD38 and HLA-DR memory CD8 T cells in HIV-
infected adults is predictive of slower CD4 T cell recovery rates during HAART 
(Hazenberg et al., 2000c). Long-term therapy reduces the absolute number of CD38+ 
CD8 T cells; conversely, an increase in CD38 expressing CD8+ cells correlates with 
progression to AIDS (Giorgi et al., 1993; Liu et al., 1997). Studies in adolescents have 
revealed analogous results (Starr et al., 2002a; Rudy et al., 2006a). However, these 
previous adolescent studies have been limited to single activation parameters and 
examination of total memory (RO+) cells.  Qualitative or quantitative differences in  
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Figure 1: Gating Scheme for Activation Markers A) CD8 or CD4 cells were gated 
into naïve (CCR7+CD27+CD45RO-) and bulk memory subsets B) memory subsets were 
then further subdivided to assess expression of the markers Ki67, HLA-DR, CD38, Bcl-2 
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immune activation between memory subsets could have important implications for 
disease mediated by HIV in adolescents.   
While the definitive causes of chronic immune activation remain unclear, 
decreased integrity of the intestinal wall during chronic HIV infection in adults has been 
associated with higher levels of circulating bacterial products such as lipoplysaccharide 
(LPS) (Brenchley et al., 2006; Papasavvas et al., 2009b; Nixon and Landay, 2010) . One 
means to detect the effect of LPS induced activation is to measure circulating levels of 
soluble CD14 (sCD14) (Lien et al., 1998). It has been shown that increased LPS directly 
correlate to increased CD38 expression (Brenchley et al., 2006; Nixon and Landay, 
2010). Furthermore, increased sCD14 has been directly correlated to an increased risk of 
mortality in adult clinical studies (Sandler et al., 2011). To date an examination of the 
interplay of immune activation, CD4 T cell depletion, CD8 T cell activation and sCD14 
has yet to be carried out in adolescent subjects.  
Here we examined the link between immune activation and viral control in HIV-
infected, HAART treated adolescents by analyzing Ki67, HLA-DR, CD38 and Bcl-2 
expression on well-defined CD8+ T memory cell subsets. Our data show that as a 
consequence of inadequate therapy adherence adolescents sustain increased viral load 
and immune activation. This work enhances our understanding of the effectiveness of 
current therapy and informs regimen design in HIV-positive adolescents. 
Materials and Methods 
2.1 Cells: The cohort consisted of 44 HIV-infected adolescents in the following groups: 15 
viremic (>50 copies RNA/ml), 17 aviremic (<50 copies RNA/ml), and 12 HIV uninfected 
subjects (Table I and Table II: Appendix). 43 additional Healthy subjects were acquired  
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Figure 2: Activation levels in Bulk memory and Naïve populations of CD8+ 
T cells. Human PBMCs were thawed and stained for lineage markers (CD3, CD4, CD8, 
CD19, CD16, CD14) memory markers(CD27,CD45RO,CCR7) and activation markers 
(CD38,HLA-DR,Ki67,Bcl-2) A) CD38 B) Ki67 C) CD38+HLA-DR+ expression was 
assessed on non-naïve CD8+ T and naïve (D-F) cells using non-parametric t-tests
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for soluble CD14 titers in healthy adolescents. Patients acquired HIV from either 
mother-to-child transmission or high-risk behavior. Healthy, age-matched subjects were  
collected at two different study sites. The University of South Florida and University of 
Pennsylvania Institutional Internal Review Boards approved the protocol for collection.   
PBMC were isolated by standard Hypaque-Ficoll separation and cryopreserved in fetal 
bovine serum (FBS; ICS Hyclone, Logan, Utah) containing 10% dimethyl sulfoxide 
(DMSO; Fisher Scientific, Pittsburgh, Pennsylvania).  
2.2 Antibodies:  Monoclonal antibodies (mAbs) for surface staining included: (i) anti-
CD4 PECy5-5, anti-CD27 APC Alexa-750, anti-CD38 APC, and anti-HLA-DR Pacific blue 
, anti-CD8 605 (Invitrogen, Carlsbad, California); (ii) anti-CD19 Pecy5 and anti-CD16 
Pecy5 (Biolegend, San Diego, California); and (iii) anti-CD45RO Qdot 705 (custom). For 
intracellular staining, mAbs included anti-Ki67 FITC and anti-Bcl-2  PE (BD 
Pharmingen, San Diego, California) and anti-CD3 TRPE (Beckman Coulter, Fullerton, 
California). Custom conjugations to quantum dot (Qdot) nanocrystals were performed in 
our laboratory as described previously (Chattopadhyay et al., 2006) with reagents 
purchased from Invitrogen.  
2.3 Flow cytometry staining assay:  Cryopreserved PBMC were thawed and rested 
overnight at 37oC, 5% CO2 in cRPMI medium at a concentration of 2x106 cells/ml. 
Subsequently, the cells were washed with cRPMI and resuspended at a concentration of 
1x106 cells/ml. The cells were washed once with PBS and stained with Aqua Blue amine-
reactive viability dye (Invitrogen) for 10 minutes in the dark at room temperature; a mAb 
cocktail was used to stain surface markers for an additional 20 minutes. The cells were 
washed with PBS containing 1% bovine serum albumin (BSA; Fisher Scientific) and 0.1% 
sodium azide (Fisher Scientific) and either fixed in paraformaldehyde (Sigma-Aldrich) or 
fixed/permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) according to the  
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Figure 3: Immune Activation is elevated in some T cell subsets  (A) Ki67 (B) 
CD38 (C) CD38+HLA-DR+ expression were assessed on memory  (Effector, Effector 
Memory, Central Memory) populations across the viremic, aviremic and HIV- subjects. 
!"#$%&'()"*+%,( -."/$+%()"*+%,(
(((((01%"*1/(((((((231%"*1/(((((4"&'$5,(
67899:(
;;(
67899:(
-."/$+%(
;;(
28(
<8(
!8(
(((((01%"*1/(((((((231%"*1/((((4"&'$5,((((((01%"*1/(((((((231%"*1/((((4"&'$5,(
(((((01%"*1/(((((((231%"*1/(((((4"&'$5,((((((01%"*1/(((((((231%"*1/(((((4"&'$5,(
((((((01%"*1/(((((231%"*1/((((4"&'$5,(
(((((01%"*1/(((((((231%"*1/(((((4"&'$5,((((((01%"*1/(((((((231%"*1/(((((4"&'$5,((((((01%"*1/(((((((231%"*1/(((((4"&'$5,(
!8(
 31 
 manufacturer's instructions. A cocktail of mAbs against intracellular markers was 
added to the fixed/permeabilized cells, which were incubated for 1 hour in the dark at 
room temperature. These cells were washed once with Perm Wash buffer (BD 
Biosciences) and fixed in PBS containing 1% paraformaldehyde (Sigma-Aldrich). Fixed 
cells were stored in the dark at 4°C until the time of collection. 
2.4 Flow cytometric analysis:  For each specimen, between 0.5 and 1x106  total events 
were acquired on a modified LSRII flow cytometer (BD Immunocytometry Systems, San 
Jose, California) equipped for the detection of 18 fluorescent parameters.  Anti-mouse 
Igk antibody capture beads (BD Biosciences) were used to prepare individual 
compensation tubes for each mAb used in the experiment. Data analysis was performed 
using FlowJo version 9.1 (TreeStar, Ashland, Oregon).  
2.5 sCD14 measurement: Previously frozen (-80°C) plasma and serum samples were 
thawed at room temperature.  Plasma samples were diluted 1:400 and serum samples 
were diluted 1:100 in calibrator diluent.  The samples were analyzed for sCD14 with R & 
D Systems ELISA kit per kit instructions. 
2.6 Statistical Analysis: Initial analyses were restricted to baseline observations. Analysis 
of variance (ANOVA) or Kruskal-Wallis tests were used to compare the activation levels 
between the 3 groups, with Tukey adjustment for multiple comparisons. Soluble CD14 
levels were compared between two groups using non-parametric tests. Correlation 
coefficients assessed the association between activation and viral load. Longitudinal 
analyses were conducted using generalized estimating equations (GEEs) with either a 
Poisson or normal distribution, as appropriate, and a log-link. Partial correlation 
coefficients were calculated to assess associations longitudinally.  All analyses were 
conducted using Stata/MP 11 . 
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Figure 4: Longitudinal assessment of Immune Activation and Turnover. 
(A) CD38+HLA-DR-(B) CD38+HLA-DR+(C)Ki67+BCL- expression in effector (gray 
squares), effector memory (black circles), and central memory CD8 T cells (gray dash 
diamond) and viral load (black dash triangle) overtime (visit days). %Activation 
expressed on the primary y-axis, viral load plotted on secondary y-axis. 
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Results 
Examination of Immune Activation in bulk memory T cell populations 
To assess T cell activation and makers of chronic immune activation, we 
assembled a cohort comprised of 15 viremic (>50 copies RNA/ml), 17 aviremic (<50 
copies RNA/ml), and 12 HIV uninfected subjects (Table I, Table II:appendix). The gating 
scheme used for activation marker discrimination Figure 1. All HIV positive subjects 
were on HAART. 9 subjects had developed drug resistance and at least two subjects were 
non-compliant with therapy after the initial time point. Subjects were assessed for 
expression of common prognostic markers of HIV disease progression and activation: 
CD38, HLA-DR, Ki67, Bcl-2. 
Previous studies in immune activation assessed marker expression on bulk 
memory and naïve cell subsets in cross-sectional samples. Therefore, we first determined 
activation levels in the naïve and memory CD8 T cell populations. CD38 expression in 
memory cells was elevated in viremic compared to both aviremic subjects (p= 0.009) 
and healthy controls (p= 0.004) (Figure 2A). Co-expression of CD38 and HLA-DR was 
elevated in memory cells but did not reach significance (Figure 2B).  We found no 
significant difference in Ki67 expression on memory cells (Figure 2C) though the viremic 
group displayed almost 3-fold higher levels than the aviremic group (p= 0.075) (Figure 
2C). We analyzed CD38, CD38/HLA-DR and Ki67 expression in the memory CD8 T cell 
population and found no correlation between levels of activation and viral load. Although 
there were no significant differences in activation in the naïve cell population (Figure 
2D-F) we did observe a bimodal distribution of CD38 levels. 
Increased Turnover in HIV+ individuals on HAART 
Next we subdivided the memory population into central memory 
CCR7+CD45RO+), effector memory (CCR7-CD45RO+) and effector (CCR7-CD45RO-)  
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Table III: Assessment of CD38 expression in CD8 Effector Cells (CCR7-
CD45RO-) 
Subject Group N      Mean           Standard 
Deviation 
Fold Change of 
Viremic compared 
to subject group  
Aviremic 28    24.99          18.54 1.9 
Viremic 32    48.81          20.96 1 
Healthy 12    22.42          14.94 2.1 !
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phenotypes in order to determine whether there was differential activation between 
these subsets. We assessed Bcl-2 expression to delineate cells undergoing turnover 
because studies have demonstrated activated T cells are pro-apoptotic. We found 
increased expression of Ki67 in the central memory subset (CCR7+CD45RO+), of 
viremic adolescents compared to aviremic (p= 0.001) and healthy subject groups (p= 
0.001) (Figure 3A). We did not find turnover in either the effector memory (CCR7-
CD45RO+), effector (CCR7-CD45RO-) ( Figure 3A). Thus in agreement with previous  
findings in adults, the central memory CD8+ T cells are more likely to be actively 
dividing in viremic adolescents compared to other memory phenotypes.  
Immune Activation in Memory Subsets 
We next examined CD38 expression in the different memory subsets. CD38 
expression on central memory CD8 T cells of aviremic adolescents was significantly 
lower than viremic (p= 0.001) and healthy controls (p= 0.046). CD38 expression was 
also increased on effector and effector memory CD8+ T cells of viremic adolescents when 
compared to aviremic (p= 0.001) and healthy controls (p= 0.001) (Figure 3B). Elevated 
CD38/HLA-DR co-expression was not observed in memory subsets (Figure 3C). Of note, 
we observed a much lower frequency of CD38/HLA-DR CD8 T cells than has been 
previously reported in adults (Giorgi et al., 1993; Hunt et al., 2003b). While we do find a 
correlation between CD8+ T cell expression of CD38 and viral load in efffector CD8 T 
cells, we do not see a correlation in total memory or other cell subsets.  
Longitudinal Changes in Activation 
 We assessed longitudinal changes in activation levels on CD8+ T cells in relation 
to changes in viral load due to poor adherence or escape. Figure 4 shows representative  
data from subjects with the largest changes in viral load and drug resistance mutations. 
CD38, CD38/HLA-DR and Ki67 expression per CD8 memory subset tracked closely with  
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Table IV: Assessment of Ki67 expression in CD8 Central Memory Cells 
(CCR7+CD45R0+)  
Subject Group N      mean              Standard 
Deviation 
Fold Change 
of Viremic 
compared to 
subject 
group 
Aviremic 28    3.32 4.06 3.8 
Viremic 32    10.20 9.14 1.0 
Healthy 12    2.40 1.29 4.5 !
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changes in viral load. In subject ZBQ 86, as the viral load increases, the percent of 
CD38, CD38/HLA-DR, Ki67 expression on total memory CD8+ T cells increases as well 
(Figure 4A, right graphs).  A notable exception to this trend was seen in donor ZAM 90.  
The level of activation increases in subject ZAM 90 as does viral load but when the viral 
load becomes undetectable at time point C, the percentage of CD38 expressing T cells 
continues to increase (Figure 4, left graph). Additionally, within each individual, specific 
memory subsets appear to be differentially affected by changes in viral load. For 
example, in subject ZBQ 86, immune activation on effector CD8 T cells does not increase  
in the presence of high viral load. The central memory subset of this donor demonstrates 
a marked increase in Ki67 levels following the viral load increase.  
  We next analyzed the data longitudinally for the entire cohort using generalized 
estimating equations (GEE) for the entire cohort. CD38 expression is 1.9 and 2.1 fold 
greater on effector cells in viremic compared to aviremic subjects (p< 0.001) and 
uninfected subjects (p= 0.004), respectively (Table III). Similarly, Ki67 expression is 3.8 
fold higher on central memory cells from viremic subjects compared to aviremics (p= 
0.001) and 4.5 fold higher than on cells in this subset found in healthy controls (p= 
0.059) (Table IV). There significant differences between groups in the effector cell subset 
with the viremic group having 1.6 fold higher expression than the aviremic group (p= 
0.002).  However, once the data are adjusted for differences in age, the changes do not 
reach statistical significance. Therefore, we find that despite therapy intervention 
activation levels remain elevated in viremic adolescent subjects. 
CD4 T cell counts and Immune Activation 
Increased immune activation is highly predictive of CD4 T cell decline; therefore, 
we sought to determine if there was a correlation between cell count and activation. We  
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Figure 5: CD4 T cell counts are inversely correlated to viral load. (A) CD4 T 
cell counts/ml of blood (B) CD4 T cell percentage in viremic (n=20) and aviremic (n=16) 
subject (C) ZBQ86 (D) ZAM 90 longitudinal assessment of CD4 T cell count and viral 
load in subjects over time  
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found negative correlations between CD4 T cell count and Ki67 (r=-0.40 p= 0.049) 
and CD38 expression (r=-0.5425, p= 0.005) on CD8 memory T cells. CD38 expressing 
central memory cells (r=-0.4776,p= 0.016) and CD4 T cell count were also negatively 
correlated. Similar to other studies we also so higher levels of CD4 T cell counts and 
percentages in aviremics. Therefore, immune activation and CD4 counts correlate 
negatively. 
Because adolescents have increased thymic output we sought to determine if this 
advantage would allow them to maintain high counts even in the presence of increased 
viral loads. We observed that at baseline CD4 T cell counts (Figure 5A) and percentages 
(Figure 5B) are higher in aviremic subjects. We next examined changes in CD4 T cell  
numbers in combination with viral load in two patients over time. In Figure 5C, the CD4 
count in subject ZBQ 86 rapidly declines from time point the first time point to the 
second in direct correlation to an increase in viral load. The steady increase in viral load 
observed in subject ZBQ 86 this subject coincides with the decline of CD4 T cell counts. 
In ZAM 90, a subject with a steady decline in viral load, the CD4 T cell count rebounds 
(Figure 5D). Overall, CD4 T cell counts track with viral load both in the subjects shown 
here and in the majority of our cohort.  Indeed, when looking at the entire cohort we 
found aviremic subjects to have higher CD4 T cell counts than viremic subjects. 
Therefore, increased thymic output may not compensate for increased viral load in the 
presence of increased activation in adolescents.  
A characteristic of HIV disease progression is increased microbial translocation 
resulting in increased levels of serum sCD14. We therefore measured sCD14 levels to 
determine if there is an association with high viral load, immune activation and CD4 T 
cell count in the adolescent cohort. Higher levels of sCD14 would indicate a similar  
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Figure 6: Soluble CD14 expression correlates with biological markers of 
disease progression. Previously frozen plasma and serum samples were thawed and 
analyzed for soluble CD14 (sCD14) with the R and D systems ELISA kit (A) sCD14 levels 
in aviremic, viremic and healthy subjects (B) correlation between viral load and sCD14 
levels in viremic subjects (C) correlation between CD4 T cell count and sCD14 levels in 
aviremic and viremic patients 
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mechanism for immune activation exists in both HIV-infected adolescents and adults.   
As shown in Figure 6A, similar to previous findings in HIV-infected adults, sCD14 levels  
in viremic adolescents are significantly higher than in aviremic subjects (p= 0.0061) and 
healthy controls (p<.0001). There is a positive correlation between viral load and sCD14 
levels (r=.569, p= 0.034) (Figure 6B), and a trend towards lower CD4 T cell counts as 
sCD14 increases (Figure 6C). When examining representative subjects, we see a direct 
relationship between sCD14 levels and viral load (Figure 7 A-B); as viral load increases, 
so does sCD14. Similarly, as activation levels change, sCD14 levels remain directly 
associated. We also see a direct relationship when levels of activation are plotted against 
sCD14 levels (Figure 7C-D). These data are confirmed when analyzing the entire cohort. 
In fact, sCD14 is directly correlated to immune activation, as defined by CD38 
expression, in each memory subset. Therefore, these data indicate that, similar to HIV-
infected adults, chronic immune activation and viral load are directly associated with 
markers of microbial translocation within HIV-infected adolescents. 
Discussion 
 In the present study, we examined activation levels (CD38+, HLA-DR+ and 
Ki67+) on CD8 T cells in infected adolescents.  This is the first report in adolescents to 
simultaneously examine each respective immune activation marker and to do so on 
defined memory subsets. We also take the first step to identify factors related to 
microbial translocation (sCD14) in adolescents. We found that in the presence of 
suboptimal therapy adolescents do not control immune activation, viral load or 
microbial translocation. Several studies suggest that CD38 is a less optimal activation 
marker in younger population but it is the most consistent in our study. Our data  
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Figure 7: Biomarkers of microbial translocation are associated with viral 
load and immune activation. Previously frozen plasma and serum samples were 
thawed and analyzed for soluble CD14 (sCD14) with the R and D systems ELISA kit. 
Soluble CD14 (sCD14) expression coincides with (A-B) viral load (dashed diamond line) 
sCD14 (solid triangle line) (C-D) and CD38 expression (black squares) sCD14 (gray 
diamond) in donors ZBQ 86 and ZAM 90. 
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demonstrates, CD38 appears to be a pan-activation marker whereas Ki67 activation is 
limited to the central memory subset in CD8 cells. Unlike other studies in adults and  
adolescents we do not see elevated CD38/HLA-DR expression in viremic adolescents nor 
do the levels of this activation pattern correlate with viral load.  
In HIV infection, CD38 remains upregulated on T cells and associates with HIV 
disease progression. This association holds true for HIV+ adults, adolescents and 
children. We confirm these findings and extend the analysis to distinctly defined 
memory subsets and show that CD38 is elevated across the effector, central memory and 
effector memory subsets. Adolescents and children are expected to have higher numbers 
of CD38 due to its role as a marker of immature T cells. Indeed we observe levels of 
almost 90% in the naïve cell population, a stark contrast between the 10% expression 
reported in adults (Giorgi et al., 1993; Emu et al., 2005). We believe that these cells are 
likely to be recent thymic emigrants and therefore express more CD38. Because there is 
increased CD38 expression in the memory compartment in infected subjects compared 
to the healthy subjects it is most likely a consequence of viral load and not age 
differences. 
CD38/HLA-DR co-expression marks immune activation and higher levels of 
expression on CD8 T cells of HIV-infected adults and children predict disease 
progression (Giorgi et al., 1993; Giorgi et al., 2002; Rudy et al., 2006a). Contrary to what 
has previously been shown in adults and adolescents we do not observe significantly 
higher levels of CD38/HLA-DR expressing cells in our cohort. Furthermore, the 
percentages we report are quite low compared to those observed in previous studies in 
adults (Giorgi et al., 1999). Globally, we see lower levels of HLA-DR in our experiments 
and attribute this to our highly stringent flow cytometric gating strategy. We exclude 
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monocytes, B cells and NK cells from the final analysis to prevent false positives and 
reduce background. We have noted that a large portion of HLA-DR is found on  
macrophages and once these cells are excluded from the analysis the levels of apparent 
HLA-DR on CD8 T cells can be reduced in some instances.  Together, these results may 
suggest that CD38/HLA-DR expression may not be the best marker of activation in 
HIV+ adolescents.  
Several previous studies have conclusively indicated that T cell turnover is 
increased in HIV-infected individuals. In HIV-positive adults, Ki67 expression is 
elevated indicating increased turnover. In adolescents, Ki67 expression has been 
reported to be 5.1 fold and 2.8 fold higher in memory and naïve CD8 T cells respectively 
(Starr et al., 2002a). Conversely, we observed no significant differences in Ki67 
expression levels or fold change in total memory and naïve CD8 T cells.  
To date, studies have not addressed immune activation in distinct memory 
subsets in adolescents, although a significant body of work exists for adult cohorts. In 
1999, Hazenberg et al, delineated CD8 memory subsets on the basis of CD27 expression 
in adults to determine if turnover rates were different in memory population (Hazenberg 
et al., 2000c).  The percentage of Ki67 expressing cells was increased in the CD27- and 
CD27+ memory subsets as well as within the naïve compartment of HIV infected 
individuals. Ki67 expression was elevated up to 20-fold in the naive CD8 T cell 
population and 7-fold in the CD27- and CD27+ memory populations. We observed 
significantly higher percentages of Ki67 in the central memory compartment but report 
no differences in other subsets.  Our smaller sample size may account for the lack of 
difference. We found a lower percentage of Ki67+ cells than reported in some studies but 
our data is consistent with the numbers in a recent report (Lederman et al., 2011). 
Another differentiating factor in our study was the use of Bcl-2 , an apoptotic marker. By 
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using Bcl-2  we are able to identify not just cells undergoing increased turnover but 
also those that are most likely activated and therefore more susceptible to apoptosis. 
We also examined other predictors of disease progression like viral load and CD8 
T cell percentages. Similar to previous studies, we reported a positive correlation 
between viral load and CD8/CD4 T cell percentage. This direct relationship may easily 
reflect increased turnover in the presence of viremia. Immune activation in the total 
memory population correlates with viral load in adults, but we saw no correlation with 
CD38/CD38+HLA-DR+ and viral load in the adolescent cohort. We do observe a 
correlation between viral load and the effector T cell subset. A lack of correlation 
between CD38 and viral load may reflect the small sample size and viral load variation in 
our cohort. Nonetheless, performing correlations studies in defined memory subsets 
gives a picture of immune activation and T cell depletion patterns. 
Recent studies have suggested that initial CD4 T cell counts above 300 cells/µl 
before therapy equate to faster cell count rebound (Perez et al., 2001). Additionally, 
adolescents have increased thymic output and higher absolute T cell counts than their 
adult counterparts, even while infected. With this in mind several clinical trials are 
incorporating early therapy initiation to increase favorable therapy outcomes. While this 
strategy may prove useful, conflicting results (El-Sadr et al., 2006)suggest early therapy 
initiation will not be the only key to the successful therapy intervention. Nonetheless, 
increased numbers of naïve CD4 and CD8 T cells in adolescents may allow for better cell 
rebound than their adult counterparts.  Importantly, activation is not elevated in naïve 
CD8 T cell subsets in our study. This may prove beneficial for adolescents who are long-
term carriers of the disease.  
Microbial translocation defined by increased LPS circulation in the plasma has 
been directly correlated to increased immune activation (Brenchley et al., 2006). LPS 
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levels directly correlate with soluble CD14 detectable in the plasma (Papasavvas et al., 
2009b). Thus, we used sCD14 as an indirect marker of microbial translocation. Similar to 
what has been observed in adults, we found elevated levels of sCD14 in viremic subjects. 
These levels of sCD14 are lower in our cohort than those in adults but are relatively 
similar to those reported in children (Wallet et al., 2010). Furthermore, sCD14 levels 
were directly correlated to immune activation in each memory subset. It is important to 
note that even in HAART treated subjects levels of sCD14 do not return to baseline. 
Indeed, increased levels of microbial translocation persist even in the presence of 
decreased viral load and increased CD4 T cell counts in treated individuals (Brenchley et 
al., 2006; Jiang et al., 2009; Papasavvas et al., 2009b; Wallet et al., 2010; Sandler et al., 
2011). Recently, sCD14 has been associated with T cell activation and mortality in HIV 
infected adults (Sandler et al., 2011). This data suggests that increased baseline levels of 
sCD14 in adolescents, even in the presence of therapy can increase the risk of death. 
Given what we know about immune activation and maintenance of microbial 
translocation, it is necessary to rethink how successful therapy outcomes are evaluated. 
Presently, successful therapy is defined by CD4 T cell count rebound, lower CD8 T cell 
numbers after treatment and reduced immune activation. These are all proven factors 
involved in HIV disease progression. Yet, as we expand our understanding of immune 
activation it is necessary to include factors that may better predict disease mortality. It is 
important to reduce immune activation and viral load in order to promote immune 
restoration but simultaneous reduction of microbial translocation may prove to be a key 
factor in maintaining this immune state.       
 Adolescents are life-long carriers HIV and are subject to life-long therapy. 
Without compliance, success levels dramatically decrease and drug resistance 
susceptibility increases. Adolescents, who are less likely to adhere to therapy, were 
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recently reported to have increased percentages of circulating CD38 T cells and to 
have had virologic failure regardless of CD4 T cell count number (Flynn et al., 2004; 
Rudy et al., 2006a). In support of this data, the majority of the subject pool in our 
adolescent cohort has been on therapy for a number of years and has yet to control viral 
load or activation while on therapy. Adolescents must remain adherent or else activation 
levels will remain high and drug resistance will occur.  
These data indicate that increased immune activation in adolescents is not solely 
due to viral load or CD4 T cell counts but rather results from a combination of complex 
interactions in the gut lumen and peripheral blood. Most of our cohort was on long-term 
therapy but the majority of these subjects still maintain high levels of immune activation. 
This is likely caused by incomplete therapy compliance, a key hindrance in successful 
treatment in adolescents. Our current study was not designed to address improvement 
strategies in therapy adherence for adolescents but this is a key point. Therapy guidelines 
must be streamlined to promote maximal adherence without jeopardizing protection. We 
believe this study will inform current therapy strategies and approaches in adolescent 
HIV research. 
 
 
 
 
 
 48 
 
Chapter 3: Elevated Immune Activation and 
Turnover in CD4+ T cells of HIV+ Adolescents 
Abstract 
 During HIV infection massive CD4 T cell depletion occurs as a result of direct 
viral killing, bystander killing, and activation-induced cell death. Depletion and 
prolonged immune activation leads to severe immune dysfunction. In adults, immune 
activation directly correlates to HIV disease progression; however, immune activation in 
adolescents is not completely understood. Here, we characterized markers of immune 
activation on CD4 T cells in a cohort of adolescent subjects including 15 viremic (>50 
copies HIV RNA/ml), 17 aviremic (<50 copies HIV RNA/ml), and 12 HIV uninfected 
subjects. We used polychromatic flow cytometry to define the immune activation profile 
of CD4+ T cells by measuring simultaneous expression of CD38, HLA-DR, Ki67 and Bcl-
2. We observed increased immune activation on total memory, effector (CCR7-CD45RO-
), effector memory (CCR7-CD45RO+) and central memory (CCR7+CD45RO+) CD4 T cell 
subsets. Increased expression of CD38+ in each memory compartment negatively 
correlated with CD4 T cell counts. CD38 expression in non-naïve (r=0.5797 p=0.002), 
central memory(r=0.4246 p=0.034) and effector memory (r=0.5339 p=0.0060) 
correlated directly to levels of soluble CD14, a marker of microbial translocation. Taken 
together, these results show that there is preferential activation across memory subsets 
and a direct relationship between viremia, activation and soluble CD14 levels in HIV+ 
adolescents. 
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Figure 8: Immune Turnover CD4 T cells memory subsets. Human PBMCs were 
thawed and stained for lineage markers (CD3, CD4, CD8, CD19, CD16, CD14) memory 
markers (CD27,CD45RO,CCR7) and activation markers (CD38,HLA-DR,Ki67,Bcl-2) 
Ki67 expression was assessed on CD4+ T memory subsets using non-parametric t-tests 
 50 
Introduction  
 Immune activation is now known to be a major underlying cause of CD4 T cell 
depletion during HIV infection and the strongest known predictor of HIV disease 
progression. Immune activation is commonly measured by elevated expression of Ki67, 
CD38 and HLA-DR. Specifically, increased Ki67 indicates entry into cell cycle, a 
characteristic of HIV infection (Sachsenberg et al., 1998a; Douek et al., 2001), and higher 
levels of circulating CD38 and CD38/HLADR expressing CD8 and CD4 T cells are 
directly associated with high viral loads and decreased CD4 T cell counts (Giorgi et al., 
1993; Liu et al., 1997; Lien et al., 1998; Hazenberg et al., 2000b; Vigano et al., 2000a). 
Persistent immune activation can severely depletes CD4 T cells and result in impaired 
immune responses.  
During acute HIV infection, and persisting into chronic infection, severe CD4 T 
cell depletion occurs in gut associated lymphoid tissues (GALT) compromising the 
integrity of the mucosal membrane (Brenchley 2004). This results in microbial 
translocation, a process that has been implicated as a key driver of immune activation 
(Brenchley 2006). In clinical studies, soluble CD14 (sCD14), a measure of LPS-induced 
activation (Lien et al., 1998) has been directly correlated to increased risk of mortality in 
adults (Sandler et al., 2011). Although levels of microbial translocation may be reduced 
after therapy administration, injury to the gut is irreversible. As a result, repopulation of 
gut memory T cells is impaired (Papasavvas et al., 2009a). These factors contribute to 
disease progression even in the presence of HAART-suppressed viral control and 
ultimately lead to immune failure (Lederman et al., 2011). 
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Table V: Assessment of Ki67 Expression in CD4 T cell memory Subsets 
* N=28 aviremics and 32 viremics 
 52 
Although HIV research has progressed greatly over the past 20 years, there are still 
understudied areas. For example, HIV disease progression is understudied in 
adolescents, a group that makes up a large number of new infections. Unique biological 
and psychological parameters in adolescents have the potential to greatly influence 
subsequent HIV disease progression.  For example, adolescents are less likely to adhere 
to strict therapy guidelines and may therefore be more susceptible to drug resistance and 
viral rebound (Futterman, 2005).  In contrast, the heightened regenerative capacity of 
the immune system is more robust in young children and adolescents (Vigano et al., 
2000b) due in part to increased thymic output in adolescents compared to their adult 
counterparts. Young adults have been shown to rebound CD4 T cell counts more 
efficiently than adults after therapy initiation (Cohen Stuart et al., 1998a; Sleasman et al., 
1999). Unfortunately, this advantage may be lost due to increased immune activation 
caused by incomplete therapy compliance. Furthermore, increased microbial 
translocation as a result of reduced gut integrity in adolescents may mark this subject 
group for immune failure even in the presence of optimal therapy. 
The response to therapy is understudied in adolescents; here we designed a study 
to address several resulting concerns. Firstly, we examined the activation levels on 
memory and naïve CD4 T cells in adolescents on HAART. We assessed activation in 
central memory, effector memory and effector T cell populations. Determining if certain 
CD4 T cell memory subsets are selectively activated could lead to a better understanding 
of HIV disease progression in adolescents. Unlike other studies, which are mostly cross-
sectional in nature, we assessed activation from baseline on longitudinal samples. Lastly, 
we assessed the relationship between sCD14 and CD4 T cell activation to determine if 
microbial translocation contributes to disease progression in HIV positive adolescents. 
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Figure 9: Expression of CD38 in Bulk memory and Naïve populations of 
CD4+ T cells. Human PBMCs were thawed and stained for lineage markers (CD3, 
CD4,CD8,CD19,CD16,CD14) memory markers(CD27,CD45RO,CCR7) and activation 
markers (CD38,HLA-DR,Ki67,Bcl-2) CD38 expression is shown on A) Naïve (B) Bulk 
memory cells p values calculated using non-parametric t-tests. 
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 Materials and Methods 
3.1 Cells: The cohort consisted of PBMCS from 44 HIV-infected adolescents 15 viremic, 
17 aviremic and 12 HIV uninfected subjects (appendix). Subjects and cells were acquired 
as detailed in Chapter 2.  
3.2 Antibodies: Antibody-staining panel was employed as described in Chapter  2               
3.3 Flow cytometry staining assay: See chapter 2 
3.4 Flow cytometric analysis:  For each specimen, between 0.5 and 1x106 total events 
were acquired on a modified LSRII flow cytometer (BD Immunocytometry Systems, San 
Jose, California) equipped for the detection of 18 fluorescent parameters. Data analysis 
was performed using FlowJo version 9.1 (TreeStar, Ashland, Oregon).  
3.5 sCD14 measurement: Previously frozen (-80) plasma and serum samples were 
thawed at room temperature and analyzed for sCD14 with R&D Systems Elisa kit per 
instructions.  
2.6 Statistical Analysis: See Chapter 2 
Results 
Turnover and activation in naïve and memory CD4 T cells 
To assess T cell activation and markers of chronic immune activation, we 
assembled a cohort comprised of 15 viremic (>50 copies RNA/ml), 17 aviremic (<50 
copies RNA/ml), and 12 HIV uninfected subjects (Appendix: Table I). The gating scheme 
of this study is shown in Figure 1. Subjects were assessed for expression of the common 
prognostic markers of HIV disease progression and activation: CD38, HLA-DR and Ki67.  
Increased Ki67 expression is a characteristic of heightened immune activation in 
both adults and adolescents. Because activated T cells are more prone to apoptosis we 
further delineated cells by lower BCL-2 expression. We observed no differences in Ki67  
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Figure 10: Expression of CD38 in Memory of CD4 T cell subsets. Human 
PBMCs were thawed and stained for lineage markers (CD3, CD4,CD8,CD19,CD16,CD14) 
memory markers(CD27,CD45RO,CCR7) and activation markers (CD38,HLA-
DR,Ki67,Bcl-2). Cells were then gated on memory phenotype and then further gated on 
CD38 expression, p-values calculated using non-parametric t-tests. 
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expression in the bulk memory, naïve or other cell subsets in cross-sectional data 
(Figure 8); however, we found significant differences in Ki67 expression in all CD4 T cell 
subsets over time. We see 2.7-fold higher expression of Ki67 in CD4 naïve cells compared 
to aviremics (p=0.005). In bulk memory cells, we observe a 1.9 fold difference between 
viremics and aviremics (P<0.001). CD4 subsets were divided into central memory 
(CCR7+CD45RO+), effector memory (CCR7-CD45RO+) and effector phenotypes. We 
saw a 3.7-fold increase in the central memory (p=0.001) and a 1.7-fold increase in the 
effector memory (p=0.038) subset compared to aviremics (Table V). Thus, unlike 
previous studies in adolescents and adults, we did not observe a difference in CD4 T cell 
turnover at baseline. However, when data was analyzed longitudinally, we identified 
increased T cell turnover in each subset with the exception of effector CD4 T cells. 
Ultimately, increased turnover in the CD4 compartment could lead to increased 
apoptosis and immune senescence.  
 Increased expression of CD38 or CD38/HLA-DR on T cells is a hallmark of 
immune activation and is often associated with high viral loads (Giorgi et al., 1993; 
Giorgi et al., 1999). We first looked at baseline levels of CD38 in each CD4 T cell subset. 
We did not observe a significant increase in CD38 expression on naïve CD4 T cells but 
we did find a biomodal distribution of CD38 expression in this cell type (Figure 9A). 
There higher CD38 expression in viremic subjects compared to aviremic in the bulk 
memory group (p=.0476) (Figure 9B). We next examined expression of CD38 on 
memory subsets at baseline. Expression of CD38 was increased on effector memory 
(p<0.001) and effector (p=0.011) cell subsets in viremic subjects compared to the 
aviremics (Figure 10). We did not find a difference in the percentage of CD38/HLA-DR 
expressed in naïve (Figure 11A), central memory (Figure 11C), effector memory (Figure 
11D) or effector cells (Figure 11E), but observed a 2-fold increase in the percentage of  
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Table VI: Assessment of CD38+/HLA-DR- expression on CD4+ T cell 
subsets 
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CD38/HLA-DR expressing bulk memory cells in viremic compared to aviremic at 
baseline (p=0.027) (Figure 11B). Thus, it can be seen that activation levels remain 
elevated in viremic adolescents on therapy. 
We next assessed longitudinal changes in activation levels on CD4+ T cells in 
relation to changes in viral load due to poor adherence or escape. Figure 5 shows 
representative data from subjects with large changes in viral load and drug resistance 
mutations. CD38 expression (Figure 12), CD38/HLA-DR (Figure 13) and Ki67+Bcl-2 
(Figure 14) expression per CD8 memory subset tracked closely with changes in viral load 
in subjects ZAN89 and ZBQ86. The pattern of activation was not as uniform in subject 
ZAM 90, who had intermittent therapy compliance and consequent drug resistance. The 
level of CD38 expressing cells increased in ZAM 90 with viral load but expression of the 
other activation markers was inconsistent. When we examined the entire cohort using 
GEE, CD38 expression was 6.9-fold higher in effector cells of viremics compared to 
aviremics (p=0.025). The effector memory compartment in the viremic group has 1.8 
fold higher levels of CD38 than the aviremic group (p<0.001). In the central memory 
compartment, aviremics had 7.4-fold lower CD38 levels than the viremic group 
(p=0.062). We found no significant differences in CD38/HLA-DR expression in CD4 T 
cells. 
Increased CD4 T cell activation and turnover correlates with lower CD4 T 
cell counts and higher CD8 T cell counts 
 Several studies have shown a correlation between activated CD4 T cells, viral load 
and CD4 T cell count, but none have determined this difference in memory subsets.  We 
chose to examine the expression of all activation markers and their relationship to cell 
count. CD38 expression was negatively correlated to lower CD4 T cell counts in each 
memory subset: central memory (p=0.0216, r=0.440), effector memory (p=0.0014 r=- 
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Figure 11: CD38+HLA-DR+ expression is elevated in some T cell subsets. 
CD38+HLA-DR+ expression were assessed on memory (A) Naive (B) Bulk memory (C) 
Central Memory (D) Effector Memory (E) Effector populations across the viremic, 
aviremic and healthy subjects. 
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0.5826) and effector (p=0.0064, r=-0.5111). Lower absolute CD4 T cell counts also 
correlated with increased turnover in the central memory and effector cell 
compartments. In contrast to other studies, we did not observe correlations between 
increased activation and viral load.    
During HIV infection, CD8 T cell counts and percentages typically increase 
dramatically as a result of increasing HIV viral load (Koup et al., 1994; Rudy et al., 
2006a). After successful HARRT therapy however, the CD8 T cell count declines 
coincident with both decreased viral load and immune activation. However, these initial 
studies were primarily performed on total memory and naïve T cell population 
(Hazenberg et al., 2000c; Flynn et al., 2004; Rudy et al., 2006a). We therefore examined 
the association between the CD8 T cell count and immune activation in CD4 T cells. We 
found a direct correlation between Ki67+CD4 T cells and the percentage of CD8 T cells 
(r=0.467 p=0.0163). We next assessed the association between CD8 T cell count and 
activation. The CD8 T cell count positively correlated with CD38 expression in the total 
memory (p=0.0378 r=0.4094) and effector memory (r=0.446 p=0.022). CD4 T cell 
compartments. Thus CD8 T cell counts are directly associated with increased Ki67 
expression and immune activation in the CD4 T cell compartment. 
A characteristic of HIV-induced immune activation and disease progression is 
decreased integrity of the intestinal wall, which can be measured by increased levels of 
sCD14 in the plasma. In Chapter 2, we have shown that the percentage of total 
CD38+CD8 and viral load directly correlate to sCD14 in adolescents and that CD4 T cell 
percentage inversely correlates with sCD14. Here, we examined how sCD14 levels 
correlated to CD4 T cell activation in the adolescent subjects.  We found that CD38+ 
levels in non-naïve (r=0.5797 p=0.002), central memory(r=0.4246 p=0.034) and 
effector memory (r=0.5339 p=0.0060). CD4 T cells positively correlated with sCD14  
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Figure 12: Longitudinal assessment of CD38+HLA-DR- expression in CD4 T 
cells.(A-C) Changes in immune activation in effector (gray squares), effector memory 
(black circles), and central memory cells (gray dash diamond)and viral load (black dash 
triangle) overtime (visit days). %Activation expressed on the primary y-axis, viral load 
plotted on secondary y-axis 
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levels in the plasma. Thus, microbial translocation may be a factor driving immune 
activation in adolescents. 
Discussion 
Immune activation is the strongest predictor of disease progression in adults, 
however; the global impact of HIV-induced immune activation is understudied in 
adolescents. In the present study we assessed the activation status of CD4+ T cells in 
HIV-infected adolescents in order to define the CD4 T cell activation signature in this 
group. In an effort to understand the dynamics of T cell turnover and immune activation 
in CD4 T cells, we used both cross-sectional and longitudinal data. Similar to our 
findings in CD8 T cells (CHAPTER 2) we find that in the presence therapy adolescents 
do not control viral replication or immune activation. We believe this result reflects the 
consequence of suboptimal therapy compliance common in adolescent subjects. Unlike 
our CD8 data, we find increased T cell activation is more prevalent in the CD4 T cell 
naïve, total memory, effector memory and central memory compartments, which is 
consistent with several studies (Orendi et al., 1998; Hazenberg et al., 2000c; Flynn et al., 
2004).  
Increased T cell turnover is a hallmark of immune activation in HIV infection. In 
adolescents, it has been shown that CD4 turnover (as measured by Ki67 expression) is 
increased in the memory and naïve T cell compartments (Cohen Stuart et al., 1998a; 
Sleasman et al., 1999; Rudy et al., 2006b). Moreover, untreated HIV-infected adults with 
increased turnover have lower CD4 T cell counts, suggesting that neither homeostatic 
nor viral induced proliferation are sufficient to sustain CD4 T cell counts (Hazenberg et 
al., 2000b; Hunt et al., 2003b). In our adolescent cohort, we did not find an increase in 
CD4 T cell turnover at baseline but observed increased expression of Ki67 in all memory  
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Figure 13: Longitudinal assessment of CD38+HLA-DR+ expression in CD4 T 
cells.(A-C) Changes in immune activation in effector (gray squares), effector memory 
(black circles), and central memory cells (gray dash diamond)and viral load (black dash 
triangle) overtime (visit days). %Activation expressed on the primary y-axis, viral load 
plotted on secondary y-axis. 
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compartments longitudinally. Of note, increased turnover in the central and effector 
memory compartment was associated with lower CD4 T cell counts over time. These 
findings are similar to a recent study in HIV-infected adults (Lederman et al., 2011) 
where cell cycling was increased in these compartments. These reports imply that 
increased turnover of central memory and effector memory cells contribute to decreased 
CD4 T cell counts. Further evidence suggests that failure to replenish memory T cell 
numbers in the central or effector memory compartment will result in immune failure 
(Teixeira et al., 2001; Robbins et al., 2009; Lederman et al., 2011). Our data shows 
increased turnover in the CD4 memory and naïve T cell compartment of adolescents. 
This suggests that CD4 T cells will either be severely depleted or exhausted before 
therapy-noncompliant adolescents reach mid-adulthood making them more prone to 
rapid disease progression. 
 In HIV infection, CD38 remains upregulated on T cells and associates with HIV 
disease progression (Vigano et al., 2000a; Wilson et al., 2004). This association holds 
true for HIV positive adults, adolescents and children. Our work has confirmed these 
findings and extended them to well defined memory subsets. We observe increased 
CD38 expression in effector, central memory, and effector memory subsets. Similar to 
our findings in naïve CD8 T cells, there appears to be a bimodal distribution of CD38 in 
naïve CD4 T cells. This expression pattern is most closely associated with age in that 
younger subjects express more CD38 and is seen regardless of HIV infection status. The 
addition of CD31, a marker of recent thymic emigrants, may help determine if these 
CD38+ naïve CD4 cells are immature T cells or truly activated.  
Many studies use HLA-DR in addition to CD38 to determine the activated state 
of T cells. We see a significant difference in CD38-HLA-DR expression on bulk memory 
CD4 T cells at baseline. This is similar to published studies in adults, which report  
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Figure 14: Longitudinal assessment of Ki67+Bcl- expression in CD4 T 
cells.(A-C)  Changes in immune activation in effector (gray squares), effector memory 
(black circles), and central memory cells (gray dash diamond)and viral load (black dash 
triangle) overtime (visit days). %Activation expressed on the primary y-axis, viral load 
plotted on secondary y-axis 
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elevated expression in treatment failures or HIV-infected (Orendi et al., 1998; Hunt et 
al., 2006) subjects compared to controls. The levels we report are much lower than that 
of 10-30% CD38/HLA-DR co-expression shown in other studies. Furthermore we do not 
observe differences in CD38/HLA-DR expression levels in any CD4 memory subset. We 
believe both lower expression and lack of statistical significance with CD38/HLA-DR 
expression may be attributed to the rigorous manner of our flow cytometric gating 
technique.  
 Microbial translocation defined by increased LPS circulation in the plasma has 
been directly correlated to increased immune activation (Brenchley 2006). LPS levels 
directly correlate with soluble CD14 detectable in the plasma. Thus, we used sCD14 as a 
surrogate marker of microbial translocation. We showed previously (CHAPTER 2) that 
sCD14 was heightened in the viremic subjects compared to aviremic. Therefore similar to 
published studies in adults and our study in adolescents sCD14 is directly correlated with 
immune activation. Being that sCD14 is correlated to increased mortality, future studies 
in adolescents should address the effects of sCD14 in the rate of disease progression. 
 In this study we identified that a subset of HIV+ adolescents on therapy do not 
control immune activation. When therapy adherence is between 90 and 95% viral 
replication is controlled and immune activation is reduced. Unfortunately, adolescents 
are less likely to adhere to therapy guidelines than their adult counterparts. As a result 
they often possess higher numbers of circulating CD38+ T cells and undergo virologic 
failure even in the presence of high CD4 T cell counts. Our data demonstrate that viremic 
adolescents on HARRT have increased activation and turnover in the majority of CD4 T 
cell subsets compared to aviremic and HIV-negative counterparts. A few questions 
remain like, what other factors account for differences in activation and viral control in 
HIV-positive adolescents? Are aviremic subjects more adherent to therapy or do they 
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possess certain biological determinants that allow them to effectively control viral 
replication in the absence of adherence? If both the HIV epidemic and potential burden 
of disease in adolescents is to be reduced, future studies must be designed to properly 
address these questions. 
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Chapter 4: Gag and Nef- specific CD8 T cell 
responses in adolescents on HAART  
Abstract 
Defining correlates of immune protection is a key factor in informing effective 
vaccine design. Robust HIV-specific CD8 T cell responses have been observed in adult 
subjects who control viral load; responses in HIV-positive adolescents, however, are less 
understood. Here, we examined HIV-specific CD8 T cell responses to Gag and Nef in 26 
HIV-positive adolescents who were intermittently compliant to HAART.  While we could 
identify Gag-and Nef specific responses in many of these subjects, we found no 
significant differences in the magnitude or proportion of cytokine producing nef or gag 
specific CD8 T cells between aviremic or viremic subjects. There was also no relationship 
observed between age and the magnitude of the total HIV-specific CD8 T cell response in 
our cohort. Our data show that adolescents on intermittent therapy produce functional 
responses.  
Introduction 
Since the identification of a temporal correlation between HIV-specific CD8 T cell 
expansion and acute viral resolution (Borrow et al., 1994; Koup et al., 1994), several 
groups have sought to identify the role of HIV-specific CD8 T cells in disease 
progression.  Multiple independent reports have demonstrated an inverse correlation 
between the magnitude of the Gag-specific CD8+ T cell response and viremia (Riviere et 
al., 1995; Ogg et al., 1998; Kiepiela et al., 2007; Rolland et al., 2008). Moreover, subjects 
who control viral load in the absence of therapy have HIV-specific CD8 T cell responses 
directed against multiple epitopes and enriched for perforin-mediated killing ability 
 69 
(Betts et al., 2001a; Migueles et al., 2002; Betts et al., 2006; Emu et al., 2008; 
Hersperger et al., 2010a). Together these findings suggest that HIV-specific CD8+ T cells 
play an important role in controlling HIV infection. Evidence for the importance of CD8 
mediated control has motivated the field to develop T cell based vaccines against HIV, 
although this strategy has not yet yielded an efficacious vaccine (Watanabe, 2003; 
McElrath et al., 2008). 
The majority of work on HIV-specific CD8 T cell responses has been performed 
in adults, and little is known about the protective role of these responses in adolescents, 
a population that makes up 50% of new HIV cases yearly (Futterman, 2005). Because 
these subjects will be lifelong carriers of HIV, it is important to understand the 
protective capacity of HIV-specific CD8+ T cells in adolescents. Whether the quality of 
the HIV-specific CD8+ T cell response is associated with disease control in adolescents 
understudied. Most reports have focused primarily on identifying antigen specificity 
through cytolytic function or IFN-γ responses (Luzuriaga et al., 1995; Buseyne et al., 
1998; Spiegel et al., 2000; Scott-Algara et al., 2001; Buseyne et al., 2005b), but a more 
detailed assessment of total HIV-specific CD8 T cell response has not been performed. 
Here, we used polychromatic flow cytometry to examine Gag and Nef-specific 
CD8 T cell responses in viremic and aviremic adolescents on therapy, focusing on 
defining the polyfunctional and cytolytic marker expression capacity of HIV-specific CD8 
T cells from these individuals. Because higher CD4 T cells counts are indicative of 
stronger CD8 responses in adults and children (Sandberg et al., 2003), we additionally 
performed analysis to determine if this trend was also apparent in adolescents. Our 
preliminary findings are not significant but show a dichotomy in the functional response: 
viremic subjects appear to have a higher percentage of Nef-responding CD8 T cell than 
their aviremic counterparts; conversely, aviremic subjects mount a more robust  
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Figure 15: HIV-specific CD8 T cell response in adolescents. Cryoperserved 
PBMCs were stimulated with Gag or Nef peptide for 6 hours in the presence of BFA. Cells 
were then stained for linage markers (CD3, CD4,CD8,CD19,CD16,CD14) memory 
markers(CD27,CD45RO,CCR7)and cytokines (IL-2,IFN-g,TNF, Perforin, MIP-1a). 
CD27+CD45RO- (naïve) cells were excluded from the analysis for the memory 
population. (A) SEB- stimulated memory CD8 T cell responses from an aviremic and 
viremic subject.  (B) The % total cytokine producing (Gag+Nef responding) populations 
were graphed for viremic (blue) and aviremic (red) subjects. (C) The average expression 
profile for the memory CD8 T cell response is graphed for IL-2,IFN-g,TNF, Perforin, 
MIP-1a 
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polyfunctional response to Gag. These results suggest that CD8 T cells in HIV-positive 
adolescents are functional and may respond differently based on specificity. 
Materials and Methods 
4.1 Subjects: Donor peripheral blood mononuclear cells were obtained from the 
laboratory of Dr. John Sleasman at the University of South Florida in compliance with 
the guidelines set by the internal review boards of both institutions. 
4.2 Staining and Stimulation Assay: Cryopreserved human PBMCs were thawed and 
subsequently rested overnight @ 37°, 5% CO2 in complete medium supplemented with 
10% FBS, 1% L-glutamine. Cells were then washed with complete medium and 
resuspended at a concentration of 1 x106 cells/mL if sufficient numbers were available. 
Brefeldin A and co-stimulatory molecules CD28 and CD49d were added at a final 
concentration of 1µg/ml. PBMCs were incubated at 37°C, 5% CO2 with overlapping 15-
mer peptide pools encompassing HIV-1 (Clade B) Gag and Nef proteins. At the 
conclusion of the incubation period conventional surface staining and intracellular 
cytokine staining was done as described in CHAPTER 2 and published previously (Betts 
et al., 2001b; Betts et al., 2006; Chattopadhyay et al., 2006). 
4.3 Antibodies: To determine cell viability, we used Aqua Blue viability dye (Invitrogen, 
Carlsbad, California). Monoclonal antibodies (mAbs) for surface staining included: (i) 
anti-CD8 Qdot 605, anti-CD19 APC-Alexa-750 and anti-CD16 APC-Alexa-750 
(Invitrogen, Carlsbad, California);  (ii) anti-CD45RO TRPE and anti-CD27 PeCy5 
(Beckman Coulter, Fullerton, California); and (iii) anti-CD4 PeCy5-5 (eBioscience) For 
intracellular staining, mAbs included anti-CD3 Q-dot 655 (Invitrogen, Carlsbad, 
California) anti-TNF PeCy7, anti-IL-2 APC, anti-Mip-1a FITC (eBioscience) and anti-
IFN-γ Alexa 700 (Invitrogen, Carlsbad, California); Perforin-Pacific Blue (Custom). 
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Figure 16: Gag-specific CD8 T cell response in adolescents. Cryopreserved 
PBMCs were stimulated with Gag for 6 hours in the presence of BFA. Cells were then 
stained for linage markers (CD3, CD4,CD8,CD19,CD16,CD14) memory 
markers(CD27,CD45RO,CCR7)and cytokines (IL-2,IFN-g,TNF, Perforin, MIP-1a). 
CD27+CD45RO- (naïve) cells were excluded from the analysis for the memory 
population. (A) The % Gag-specific responding populations were graphed for viremic 
(blue) and aviremic (red) subjects. (B) The average expression profile for the HIV-Gag-
specific CD8 T cell response is graphed for IL-2, IFN-g, TNF, Perforin, MIP-1a 
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4.4 Flow cytometric analysis:  Analysis was performed as discussed in Chapter 2. 
Briefly, for each specimen, between 300,000 and one million total events were acquired 
on a modified LSRII flow cytometer (BD Immunocytometry Systems, San Jose, 
California) equipped for the detection of 18 fluorescent parameters.  Anti-mouse Igk 
antibody capture beads (BD Biosciences) were used to prepare individual compensation 
tubes for each mAb used in the experiment. Data analysis was performed using FlowJo 
version 9.1 (TreeStar, Ashland, Oregon) and SPICE version 5.21. Boolean gating analysis 
was performed for each functional parameter. This analysis resulted in 32 possible 
permutations of the 5 measured functions.  Events measured negative for all functional 
parameters and perforin single positive cells were ignored for analysis. By excluding 
perforin single positive cells it can be assured that perforin examined within the analysis 
is HIV-specific and present in activated memory CD8 T cells expressing at least one 
other function. Naïve CD8 T cells (CD27+CD45Ro+) were excluded from the analysis 
4.5 Statistics: Graphing and Statistical analysis was performed using GraphPad Prism 
software (version 5.0a). Total magnitude and functionality were compared between the 
two subject groups using non-parameteric t-tests (Mann-Whitney). Correlations were 
based on Spearman correlation coefficients.  
Results 
Studies in HIV elite controllers have shown that two types of CD8+ T cell 
responses correlate with control of viremia:  highly polyfunctional cells characterized by 
simultaneous production of IL2, IFN-γ, TNF, MIP1-β, and CD107a, and also CD8+ T cells 
producing perforin in combination with other measured functions (Zimmerli et al., 
2005; Betts et al., 2006; Saez-Cirion et al., 2007; Migueles et al., 2009; Hersperger et al., 
2010b). As shown in Figure 15A, our panel was able to detect polyfunctional CD8+ T cell 
responses after stimulation with SEB, indicating that both viremic and aviremic  
 74 
 
 
Figure 17: Nef-specific CD8 T cell response in adolescents. Cryoperserved 
PBMCs were stimulated with Nef for 6 hours in the presence of BFA. Cells were then 
stained for linage markers (CD3, CD4,CD8, CD19 ,CD16, CD14) memory markers 
(CD27,CD45RO,CCR7) and cytokines (IL-2,IFN-γ,TNF, Perforin, MIP-1α). 
CD27+CD45RO- (naïve) cells were excluded from the analysis for the memory 
population. (A) The Gag-specific responding populations were graphed for viremic (blue) 
and aviremic (red) subjects. (B) The average expression profile for the HIV-Nef-specific 
CD8 T cell response is graphed for IL-2,IFN-γ,TNF, Perforin, MIP-1α  
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adolescents were capable of eliciting polyfunctional T cell responses. Although the 
aviremic subjects appeared to have higher responses, we found no statistical difference 
in the total CD8+ T cell response frequency in the two subject groups (Figure 15B). We 
next examined the polyfunctional profile of the HIV-specific CD8 T cells in aviremic and 
viremic subjects. The aviremic group appeared to have a higher proportion of 3-function 
producers (IFN-g +MIP+TNF+) but this difference was not significant (Figure 15C). We 
next assessed the total response (Gag+Nef) in viremic and aviremic subjects. Therefore, 
we do not see a difference in total magnitude or polyfunctionality between viremic and 
aviremic subjects on therapy.  
We next examined the relative contribution of Gag and Nef peptide pools to the 
HIV-specific CD8 T cell response. Aviremics appear to have a higher Gag-specific CD8 T 
cell response than their viremic counterparts (Figure 16A) but this difference was not 
significant. Furthermore, the response was dominated by 3- (IFN-γ +MIP-1α +TNF+), 2- 
(IFN-γ +MIP−1α +), and 1-function producers (MIP-1α) (Figure 16B). These same 
functional combinations were also dominant within viremic subjects. When we 
examined the Nef-specific response, it appears as if a higher proportion of CD8 T cells in 
viremics responded compared to the aviremics, but this difference was not significant 
(Figure 17A). Unlike the aviremic Gag-specific response, single function cells dominated 
the viremic Nef-specific CD8 T cell response.  
We therefore specifically examined the relative contribution of these two 
different populations to the CD8 response in the viremic and aviremic subjects.  First we 
assessed the presence of the most highly polyfunctional cells, measured here as those 
cells producing IFN-γ, TNF, IL-2, and MIP1-α with or without perforin (CD107a was not 
measured in our panel). As shown in Figure 18A, very few highly polyfunctional HIV-
specific CD8+ T cell responses were detected in the viremics and aviremics. Interestingly,  
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Figure 18: Perforin upregulation and polyfunctionality in the total HIV-
Specific CD8 T cell response. (A) The magnitude and  (B) proportion of the HIV-
specific CD8 T cell response to Gag and Nef peptide pools was calculated for viremic 
(blue) and aviremic (red) subjects and plotted.  
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viremic subjects had a larger proportion of perforin-producing CD8 T cells than their 
aviremic counterparts (Figure 18B).  Therefore, this suggests that even though viremic 
subjects have cytolytic function they may be less likely to control viral load in the absence 
of robust polyfunctional responses.  
	  	   We next looked at the proportion of cells producing perforin in response to Gag 
or Nef peptide. A higher proportion of Nef-and Gag specific CD8 T cells from viremic 
subjects produce perforin compared to their aviremic counterparts (Figure 19A-B). It is 
of note that a smaller proportion of Nef and Gag responding CD8 T cells in viremics are 
polyfunctional compared to those in aviremics (19A-B). As shown in Figure 19C, the 
magnitude of the Nef response is low in both subject groups but the viremics display a 
more robust and polyfunctional response. Conversely, Gag-specific CD8 T cells respond 
with higher magnitude than the aviremics (Figure 19D).  Similar to studies in adults 
(Betts et al., 2006; Hersperger et al., 2010b; Hersperger et al., 2011), these data suggest 
that a more polyfunctional response to HIV proteins is a characteristic of subjects with 
low viral loads. Unlike these previous studies we show subjects with higher viral load 
trend towards a higher proportion of perforin producing cells. 	  
 In children and young adults, age is often a strong correlate with functional 
responses and disease parameters (Buseyne et al., 1998). However, these studies were 
limited to IFN-γ ELIspot assays that do not accurately depict the complexity of an 
immune response. Therefore, we examined whether age was related to total T cell 
functionality. We found no significant correlation between age and HIV-specific CD8 T 
cell responses when including multiple functional outputs (20A-C). We next assessed the 
relationship between CD4 T cell percentage and the HIV-specific CD8 T cell response.  
We found a trend towards an inverse relationship between the CD4 T cell percentage and 
CD8+ T cell responses to the HIV peptides (Gag, Gag+Nef) (Figure 21A-B). We observed  
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Figure 19: Perforin upregulation versus polyfunctionality of Gag and Nef-
Specific CD8 T cell responses. (A-B) The proportion and  (C-D) magnitude of the 
HIV-specific CD8 T cell response to Gag and Nef peptide in viremic (blue) and aviremic 
(red) subjects. Where (+) indicates the proportion of the response belonging to perforin 
production and (-) is calculated by summing across all functional combinations with the 
exclusion of perforin 
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a trend towards a direct relationship between CD4 T cell percentage and the Nef 
response (Figure 21C). We did not find a relationship between CD4 T cell count and 
antigen response (Figure 22A-C). Together these results indicate that HIV-specific CD8 
T cell functionality is not directly influenced by subject age or CD4 T cell count.   
Discussion 
 HIV-specific CD8 T cell responses are extensively studied and are a likely 
correlate of immune protection in HIV-positive adults. While studies have advanced over 
the past few years in our understanding of the CD8 T cell response, there is a paucity of 
similar studies in adolescents. Being that adolescents will be long term carriers of the 
disease, it is therefore important to establish what key factors in the CD8 T cell response 
correspond to viral control. Determining these factors will help tailor future vaccine 
design by exposing what specific responses are necessary for efficient viral control.  In 
this study, we measured Gag and Nef-specific responses in HIV-positive adolescents on 
therapy. We find that adolescents on therapy are capable of making functional responses 
to both Gag and Nef peptides. 
Gag-specific CD8 T cell responses have been shown to be a correlate of viral 
control in HIV-positive adults and infants. These responses are enriched in slow 
progressors who maintain low viral loads (Klein et al., 1995; Riviere et al., 1995; Edwards 
et al., 2002). We did not observe a difference between Gag-specific responses across 
subject groups. The reasons for this lack of significance were likely low subject number 
or the high variability in response patterns. We did however observe that the aviremic 
subjects appeared to exhibit a more robust and polyfunctional response to Gag. This is 
supported by previous reports in elite controllers where subjects with lower viral loads 
demonstrate responses with higher magnitude and polyfunctionality (Betts et al., 2006; 
Hersperger et al., 2010a). 
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Figure 20: There is no relationship between age and CD8 T cell parameters. 
(A) The average proportion of cytokine producing HIV-specific CD8 T cells (B) CD8 T 
cell count within each subject was plotted against each subjects age. 
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Nef-specific CD8+ T cell responses as detected by IFN-γ ELIspot have been shown to 
be robust in HIV-positive children on therapy (Sandberg et al., 2003). We therefore 
chose to examine the Nef-specific response in HIV-positive adolescents. We did not find 
any significant differences in Nef-specific responses between the viremic and aviremic 
groups. Unlike the Sandberg study, which used ELIspot analysis, we determined Nef-
specific CD8 responses using multiparameter flow cytometry. As such, accounting for 
non-IFN-γ producing HIV-specific CD8+ T cells in HIV infected adolescents may change 
our understanding of the association between HIV-specific CD8+ T cells and viral 
control in HIV infected adolescents. 
Adolescents have higher thymic output of naïve T cells, which allows for better 
naïve CD4 T cell recovery while adherent to therapy (Cohen Stuart et al., 1998b; Douek 
et al., 1998; Sleasman et al., 1999; Vigano et al., 2000b). This advantage can often 
correlate to decreased viral load and improved CD8 T cell responses. Indeed subjects 
with CD4 T cell counts ranging 400-1500 cells/µl have increased breadth and magnitude 
of HIV-CD8 T specific T cell responses as determined by ELIspot (Sandberg et al., 2003). 
The results of this report are not surprising in that higher circulating CD4 T cells often 
correlate to a more polyfunctional CD8 T cell response in adults (Klein et al., 1995; 
Pantaleo et al., 1995; Betts et al., 2006). Although the subjects in our cohort had CD4 T 
cell counts ranging from 136-1383 cells/µl and a mean CD4 T cell count of 577 cells/µl, 
we did not observe robust responses as seen in previous reports. A key difference 
between our study and studies in adults is that the subjects in our cohort were on 
therapy- and notably were often only intermittently compliant. It has been shown that 
functional responses decay after therapy initiation, providing the subjects are compliant 
(Casazza et al., 2001). Therefore, the presence of healthy CD4 count levels may only 
predict polyfunctionality in the absence of therapy. This area should be investigated  
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Figure 21: There is no relationship between CD4 T cell percentage and HIV-
specific CD8 T cell response. (A) The average proportion of cytokine producing HIV-
specific CD8 T cells (B) Gag-specific (C) Nef-specific are plotted versus the CD4 T cell 
percentage from each respective subject
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further to determine if higher CD4 T cell counts correlate to a more functional HIV-
specific CD8 T cell population in HIV-positive adolescents.  
As stated previously, CD8 T cells in subjects on HAART retain functionality but 
have reduced response magnitude to HIV peptides. Aviremic subjects within our study 
have robust CD8 T cell responses. Additionally, a large proportion of these responses are 
polyfunctional. It is possible that the functional responses we see in aviremics are due to 
intermittent rounds of replication due to non-compliance. However, we do not have a 
pre-therapy time point available to compare pre-treatment functionality, which would 
allow us to determine if aviremics initially had higher responses that are now steadily 
decreasing as expected.  
A growing body of literature supports the hypothesis that cytolytic killing ability 
is a correlate of immune control in HIV-positive subjects (Migueles et al., 2002; 
Hersperger et al., 2010a; Hersperger et al., 2011). A subset of individuals termed elite 
controllers sustain viral control and have superior ability to upregulate cytolytic 
molecules like perforin in response to HIV stimulation. Here, we identified a higher 
proportion of perforin production in the viremic adolescents compared to aviremic 
subjects in response to both Gag and Nef. In fact, the proportion of perforin production 
in the viremics for both peptides is similar to that of the perforin proportion in elite 
contorollers (Hersperger et al., 2010a). Moreover, the proportion of the response that is 
perforin positive in aviremic subjects is similar to that of chronic progressors. Further 
study of additional adolescents, particularly ones compliant to therapy, will be necessary 
to determine the relationship between perforin and viral load, and whether the 
associations observed in adults are different than those found in adolescents. 
CD8 T cell mediated control is thought to be a potential factor in controlling viral 
replication and dictating disease outcome. Although we do not see any significant 
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associations of polyfunctionality in HIV-positive adolescents, this area should 
continue to be researched. A larger study population should be used to address the 
potential impact of HIV-specific CD8 T cells in HIV-positive adolescents. Future studies 
should be longitudinal in design and include assessment of several factors that 
correspond to CD8 T cell mediated control like HLA types, escape mutations and virus 
specific responses to determine if certain adolescents are more prone to disease 
progression than others.  
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Figure 22: There is no relationship between CD4 T cell count 
and antigen-specific CD8 T cell response. (A) The average 
proportion of cytokine producing HIV-specific CD8 T cells (B) Gag-specific (C) Nef-
specific are plotted against the CD4 T cell count from each respective subject.
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Chapter 5: Discussion and Implications 
Immune Activation and Turnover in adolescents  
In HIV infection, increased immune activation as indicated by elevated 
expression of CD38 and CD38/HLA-DR co-expression in memory CD4 and CD8 T cells 
is a key driver of disease progression in adults (Giorgi et al., 1993; Liu et al., 1997; Orendi 
et al., 1998; Giorgi et al., 2002; Emu et al., 2005; Hunt et al., 2008). Here, we assessed 
immune activation in memory T cell subsets of HIV positive adolescents in order to 
assess how differential therapy adherence coupled with enhanced thymic output may 
influence HIV-induced immune activation. Our results show increased expression of 
CD38 in all memory subsets of viremic adolescents that does not decrease over time in 
the presence or absence of effective antiretroviral therapy. Unlike other reports, 
activation defined by CD38/HLA-DR is less pronounced in our study and confined to the 
bulk memory CD4 T cell subset. 
In addition to chronic immune activation in adolescents, we observed increased 
cell cycling (Ki67) in central memory CD8 T cells and all CD4 T cell subsets. Increased T 
cell turnover or cycling as indicated by Ki67 expression is a hallmark of HIV infection 
and subsequent disease progression (Mohri, 1998; Sachsenberg et al., 1998b; Cohen 
Stuart et al., 2000). T cell cycling typically normalizes after therapy initiation 
(Hazenberg et al., 2000c); however, in our study, the subjects were poorly adherent to 
therapy and therefore maintain elevated levels of Ki67 expressing CD8 T cells. This 
suggests that suboptimal therapy compliance impairs T cell turnover normalization. 
These results are similar to previous works by Rudy, et al, where continued activation 
and turnover were characteristics of adolescents who were not adherent to HAART 
(Rudy et al., 2006a; ATN 061 B.Rudy, J. Sleasman, C. Wilson). It is important to note 
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that despite high CD4 T cell counts and viral suppression, subjects with high Ki67 
expression are characteristically more prone to immune failure.   
As a result of increased activation and turnover in HIV infected adults, CD4 and 
CD8+ T cells are driven to immune senescence which impairs the immune response (Sieg 
et al., 2008).  It is unclear, however, whether immune senescence occurs similarly in 
HIV-infected adolescents. In future studies, we could assess immune senescence through 
the assessment of CD57 and CD28 expression, as well as telomere length and telomerase 
activity in HIV infected adolescents (Effros et al., 1996; Brenchley et al., 2003; Appay et 
al., 2007). 
 In the setting of HIV infection, a large number of CD4+ T cells are depleted due to 
a number of reasons including direct killing by virus, bystander cell death, activation 
induced cell death, and CD8 T cell mediated killing (Hazenberg et al., 2000a; Douek et 
al., 2002; Silvestri and Feinberg, 2003). However, because adolescents have increased 
thymic output, heightened production of naïve CD4+ and CD8+ T cells (Smith et al., 
2000; Vigano et al., 2000b; Rudy et al., 2001) they may be able to better compensate for 
HIV-induced depletion. Indeed, while on therapy HIV-infected adolescents recover their 
CD4+ T cell counts more effectively and to slightly higher levels than their adult 
counterparts. Moreover, in the presence of controlled viral replication and decreased 
immune activation, adolescent subjects experience decreased instances of viral 
recrudescence (Douglas et al., 2000; Starr et al., 2002a; Rudy et al., 2006a). However, 
when activation is not controlled, the advantage of increased thymic output is lost and 
virus rebounds.  These findings highlight the immunological importance of maintaining 
effective antiretroviral therapy in HIV infected adolescents. 
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De-intensification: A means to promote adherence 
HIV-infected adolescents are less likely to adhere to therapy guidelines compared 
to HIV-infected adults (Futterman, 2005). Suboptimal therapy compliance can lead to 
drug resistance, viral breakthrough and increased immune activation. Our data in 
CHAPTERS 2 and 3 confirm increased immune activation in adolescents on suboptimal 
therapy.  Importantly, our results further highlight the critical need to ensure that HIV-
infected adolescents maintain effective therapy. These results suggest that poor 
adherence in adolescents subjects them to continuous rounds of virologic failure, making 
them more prone to rapid disease progression than therapy adherent adults. Therefore, 
one of the key short-term factors to successful treatment of adolescents is increasing 
adherence.  
De-intensification strategies are being explored in order to promote adherence in 
adolescents (ATN 061, B. Rudy, J.Sleasman, C. Wilson study PIs). The goal of de-
intensification is to identify the minimum optimal drug combination and dosage strategy 
needed to establish and sustain viral control. Once virologic control is established, drugs 
are removed from the regimen to decrease side effects and promote adherence. A goal of 
this thesis was to determine the levels of immune activation in adolescent subjects 
currently on therapy in order to serve as a baseline comparison for de-intensification 
studies. However, one must consider whether the results from carefully controlled de-
intensification studies will translate to success in the clinic.  As such, to ensure success, 
de-intensification strategies should be introduced coincident with both adolescent health 
counseling to ensure adherence and careful monitoring of the immunologic and virologic 
status of individuals receiving de-intensified therapy. 
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Is adherence the ultimate answer? 
Adherence to medication has been shown to be the only factor that predicts viral 
control in adolescents (Sleasman et al., 1999; Starr et al., 2002a; Rudy et al., 2006a). 
Collectively, our data support the need to improve therapy adherence in HIV-positive 
adolescents. However, if adherence is achieved, it may not produce the same benefits as 
seen in chronically infected adult counterparts long-term.  
The factors contributing to long-term success in HAART-treated adults are 
unknown and fairly understudied.  A recent report in HAART-suppressed subjects 
showed that increased CD4 T cell depletion, microbial translocation and immune 
activation were linked to immune failure in therapy adherent adult subjects. Not only 
were these studies conducted 7 years post therapy initiation, but all subjects durably 
suppressed viral replication (Lederman et al., 2011). This suggests that therapy 
adherence may not be the only key to long-term survival. Considering that virologic 
control may need to be maintained in adolescents for over 20 years (and throughout 
adulthood), it is premature to assume that adherence alone will equate to long-term 
protection.  
Functional Responses 
Although polyfunctional HIV-specific CD8 T cell responses have been shown to 
correlate with viral control in infected adults (Betts et al., 1999; Emu et al., 2005; Betts et 
al., 2006), we did not find this relationship in our adolescent cohort. There was no 
significant difference between Gag or Nef-specific CD8 T cell responses in adolescents 
who controlled virus versus those who did not. This could be for several reasons; (i) 
adolescents have less robust functional responses than adults (Buseyne et al., 2005a); 
(ii) HIV exposure may cause some basic T cell functions like proliferation and cytokine 
production to be impaired (Autran et al., 1997b; Connick et al., 2000); (iii) our study 
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power was too low to properly access differences in function. To determine if there is a 
correlation between function and viral control future studies should be of the 
appropriate power. Functional responses to other HIV viral proteins, CMV and EBV 
should be determined to understand the breadth of the CD8 response in HIV-positive 
adolescents. Viral control is not solely dictated by functional responses. Indeed, HLA 
types have been shown to confer protection against disease progression (Carrington et 
al., 1999; Altfeld et al., 2006; Emu et al., 2008). Therefore, future studies should also 
involve HLA typing to determine if the presence of certain MHC loci equate to superior 
viral control.  
Microbial Translocation  
 This body of work is the first to define the relationship between immune 
activation, viral load and microbial translocation in adolescents. Similar to results in 
adults, my findings indicate elevated sCD14 levels in viremic adolescent subjects and 
direct correlations between sCD14 and viral load. Contrary to what has been seen in 
other reports concerning adolescents (Papasavvas et al., 2009b; Wallet et al., 2010), we 
see a correlation between sCD14 and CD38 expression in T cell memory subsets. This 
thesis has thus laid the groundwork for future studies looking to determine a 
relationship between microbial translocation and disease progression in adolescents. 
Soluble CD14 has been associated with increased risk of mortality in adults, but it 
is not the only marker of microbial translocation (Nixon and Landay, 2010). LPS, a 
potent immunostimulatory toxin, is the most direct indicator of microbial translocation. 
Several studies have reported elevated levels of LPS in chronically infected subjects and 
those with AIDS. In the few studies concerning microbial translocation in HIV-positive 
children and infants, levels of LPS and sCD14 are elevated (Wallet et al., 2010; 
Papasavvas et al., 2011). These levels often persist in the presence of suppressed viremia, 
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increased CD4 T cell counts and decreased immune activation. This suggests that gut 
injury during HIV-infection promotes ongoing translocation of microbial products even 
under conditions of relative viral control (Nixon and Landay, 2010). Inflammatory 
factors like IL-6 and hs-CRP are associated with disease progression (El-Sadr et al., 
2006) and increased risk of opportunistic infections in HIV infected-adults (Rodger et 
al., 2009). Long-term studies in adolescents are needed to determine the overall effects 
these factors may have on HIV disease prognosis. 
The secondary lymphatic tissue plays a pivotal role in immune system 
homeostasis (Kaldjian et al., 2001). It is estimated that ~90 % of CD4 T cell reside in 
secondary lymphoid tissue, poised to respond to immunological threats. During HIV 
infection massive CD4 T cell depletion occurs in the intestinal mucosal tissue and 
lymphoid tissue resulting in impaired adaptive immune responses and the disruption of 
lymph node architecture (Brenchley et al., 2004; Zeng et al., 2011). Widespread damage 
to the gut is thought to be the driving force behind microbial translocation, a hallmark of 
pathogenic infection (Brenchley et al., 2006). The mucosal CD4 T cell compartment is 
not restored effectively by HAART and will greatly impact subjects longitudinally even if 
they are adherent to therapy.  The impact of prolonged gut damage is an issue in 
understanding adolescent HIV disease progression.  
Our cohort consisted of individuals who acquired HIV either at birth or through 
risky sexual behaviors. Key differences in the routes of infection in these subjects may 
warrant independent studies in each population. It has been shown that early cycles of 
viremia during infancy may destroy collagen networks needed for normal development 
of the human gut (Schacker et al., 2002; Neu, 2007; Estes et al., 2008). This suggests 
that early on the immune response in perinatally infected youth may be impaired due to 
insufficient development of the intestinal microenvironment. Therefore, studies should 
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be designed to specifically address the competence of the immune system in 
behaviorally infected adolescents compared to perinatally infected adolescents to 
determine the long-term effects resulting from gut damage. It is possible that the 
immunodepletion that takes place in the gut will have differential affects on immune 
responses and disease progression in these two subject groups.  
Prolonged sCD14 production induced by microbial translocation has been linked 
to deficient CD4 T cell reconstitution (Marchetti et al., 2008) and HIV associated 
inflammatory disorders (Ancuta et al., 2008; Nixon and Landay, 2010). As stated 
previously, injury to the intestinal epithelium is not reversed by therapy. Being that 
microbial translocation is one of the underlying causes of immune activation, the 
strongest predictor of disease progression, future studies should address ways to repair 
intestinal damage incurred by HIV infection. Probiotics may be the first step to repairing 
injured gut and have been used in individuals with gastrointestinal disorders to restore 
an effective gut barrier. Researchers are presently examining the use of probiotics as a 
means to reconstitute immune cells in the gut. A recent study showed that probiotic 
consumption boosted CD4 T cell recovery (Irvine et al., 2010). Extension of these 
probiotic studies could help with immune reconstitution and minimize extended damage 
to the gut.  
Conclusion 
This body of work has shown that increased immune activation is present in 
adolescents undergoing suboptimal therapy. Follow up studies should involve larger 
populations of subjects to allow for increased statistical power and inter-cohort 
comparisons between immune capabilities of behavioral and perinatally infected 
subjects. This study highlights the importance of finding alternate strategies for the 
control of HIV replication in HIV-positive adolescents.  Improving adherence, 
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identifying alternative treatments and understanding gut dynamics in HIV-positive 
adolescents is pivotal if we hope to reduce disease progression and improve the health 
quality of the growing HIV-positive population. 
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Appendix 
Table I: Detailed information of HIV+ Adolescent Subjects  
 
Subject Date Age Gender
Ethnici
ty Transmission Mode CD8%
Absolute 
CD8 CD4%
Absolute 
CD4 Virus RNA
Date of 
Initial ART
ZAB90 06/01/10 16 F B perinatal 55 1001 24 481 82,600 2003
06/22/11 15 65 1938 10 11/04 838
11/29/11 15 ND ND ND ND 15,100
08/24/10 17 52 805 26 399 1,820
03/30/11 18 46 274 32 189 55,889
04/18/12 19 46 511 38 426 39618
ZAJ90 07/13/10 16 F W perinatal 51 895 36 631 <50 2004
ZAL88 06/28/11 19 F B perinatal 49 908 26 487 <50 2005
09/27/09 15 50 751 19 280 2,150
04/18/10 16 57 679 16 191 6,556
05/16/10 16 52 587 17 192 6,550
07/11/10 16 49 610 21 261 <50
11/06/11 17 53 1082 22 436 96
03/07/10 17 58 742 19 243 54,300
05/16/10 17 62 768 16 198 167,000
01/09/11 18 59 797 14 194 407,000
03/11/12 19 49 1165 18 416 <50
03/10/13 20 38 1522 26 1,044 <48
11/10/13 20 ND ND 33 837 <48
05/23/10 13 63 2762 17 745 <50
12/05/10 13 62 2012 19 621 1,690
03/03/13 16 57 1920 21 708 <48
02/06/11 16 42 521 40 495 6,450
08/19/12 17 35 470 31 419 <48
09/19/10 13 36 523 28 401 <50
08/19/12 15 37 552 28 415 <48
ZAG89 M B perinatal 2003
ZAF92 F B perinatal 2003
ZAN89 F B perinatal 2005?
ZAM90 F B behavioral 2003
ZAQ91 F B perinatal 1992
ZAO93 F B perinatal ND
ZAR93 M B perinatal 2002
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06/26/11 21 29 273 14 136 <50
02/05/12 22 44 763 11 186 4,422
03/11/12 22 45 383 13 112 25,716
08/12/12 22 50 618 10 122 15,134
11/18/12 22 41 392 9 91 15,300
ZBS93 12/14/11 14 M B perinatal 45 579 26 571 <50 1994
ZBV93 10/11/11 14 M W perinatal 30 425 33 469 <50 1997
ZBW88 11/01/11 19 M H perinatal 35 857 36 891 69 1998
ZBX87 12/11/11 20 M W perinatal 38 1346 31 1,110 <50 ND
01/17/12 22 38 1167 27 831 169
09/12/12 22 ND ND 29 1,207 <50
ZCA92 12/14/11 15 F W perinatal 64 1882 15 435 26,100 1998
ZCB91 12/20/11 16 F B perinatal ND ND 17 677 13,800 2007
03/08/12 13 55 842 18 274 3,789 1995
08/12/12 13 49 716 26 371 <48
09/09/12 13 48 698 21 307 <400
02/26/12 12 28 825 29 848 <400
04/15/12 12 27 766 32 901 <50
02/10/13 13 28 665 31 731 <48
ZCL86 08/15/12 22 M B behavioral ND ND 22 240 3,984 N/A
ZCM88 02/13/13 21 M B perinatal 26 464 30 522 <48 1995
ZCN95 09/01/13 14 F H perinatal 24 408 36 620 <48 ND
ZCR91 03/13/13 18 F B behavioral 48 1112 21 497 29,800 N/A
ZDA92 09/29/13 17 F W behavioral 44 893 20 407 31,800 N/A
09/29/13 19 45 901 35 713 >750,000
01/12/14 20 34 460 43 587 1,130
ZBQ86 F B perinatal 2002
ZCE95 M B perinatal
ZBY86 F B perinatal 1996
ZDE90 M B behavioral N/A
ZCG96 M W perinatal 1996
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03/14/10 13 22 608 50 1,383 <50
09/18/11 14 20 484 54 1,284 <50
ZAU93 05/09/10 13 M B perinatal 41 (4/3/06)
689 
(4/3/06)
31 
(4/3/06)
521 
(4/3/06) <50 1998
02/23/10 14 54 976 16 289 2,310
08/02/11 15 52 894 18 313 2,460
10/19/11 45 1061 16 388 <50
11/08/09 10 35 1312 35 1,304 5,730
01/23/11 12 30 700 46 1,079 10,300
02/05/12 13 43 1172 33 907 574
11/22/09 18 37 579 22 340 55,400
08/15/10 19 16 264 30 499 <50
ZAZ86 01/31/10 20 M B perinatal 29 976 26 875 <50 2002
ZBA86 08/24/10 20 F B behavioral 61 530 17 149 7,130 2006
02/23/10 21 ND ND 24 226 111,033
07/13/10 21 43 663 26 401 1,410
ZBC90 06/08/10 16 F B behavioral 29 1079 43 1,600 <50 2006
05/07/10 21 53 1340 30 759 <50
08/07/10 21 55 1485 27 749 <50
11/21/10 21 55 1445 27 701 <50
06/15/10 15 48 1214 25 633 1,340
10/11/11 16 48 898 23 428 8,720
ZBG97 07/31/11 10 M B perinatal 41 971 32 769 <50 2007
ZBI89 09/07/10 17 F W behavioral ND ND 14 690 48,130 2006
08/09/11 8 52 792 27 419 1,420
08/23/11 8 49 689 ND ND <50
ZBL91 02/01/11 16 F B perinatal 53 851 28 462 1,310 1996
ZAS93 F B perinatal 1994
ZAW95 M B perinatal 1996
ZAV92 F B perinatal 1994
ZBB85 F B perinatal 2006
ZAX87 M B behavioral 2006
ZBF91 M B perinatal 1997
ZBE85 M W behavioral 2003
2007ZBJ99 F H perinatal
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